Search by Journal
- HOME
- > Search by Journal
- > Journal of Japanese Society of Pharmaceutical Oncology
Journal of Japanese Society of Pharmaceutical Oncology
Volume 41, Issue / 2025
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
SL1. For "Co-creation" making the new treatment with patients 森和彦 Journal of Japanese Society of Pharmaceutical Oncology 41: 1-1, 2025. |
|---|
|
|
SL2. Expectation to α generation 高木啓吾 Journal of Japanese Society of Pharmaceutical Oncology 41: 2-2, 2025. |
|---|
|
|
SL3. Professional ability and duty - of contribution - pharmacist to next-generation medical care 武田泰生 Journal of Japanese Society of Pharmaceutical Oncology 41: 3-3, 2025. |
|---|
|
|
EL. Cancer measures of Kanagawa 津島志津子 Journal of Japanese Society of Pharmaceutical Oncology 41: 4-4, 2025. |
|---|
|
|
S1-1. A summary of this business and the future prospects 橋場元 Journal of Japanese Society of Pharmaceutical Oncology 41: 6-6, 2025. |
|---|
|
|
S1-2. Point (about patients with general remarks, cancer correspondence) of this manual utilization 西村佳子 Journal of Japanese Society of Pharmaceutical Oncology 41: 7-7, 2025. |
|---|
|
|
S1-3. Point (colon cancer, lung cancer, stomach cancer, breast cancer, liver cancer) of this manual utilization 櫻下弘志 Journal of Japanese Society of Pharmaceutical Oncology 41: 8-8, 2025. |
|---|
|
|
S1-4. Point (community medical care cooperation, others) of this manual utilization 槇枝大貴 Journal of Japanese Society of Pharmaceutical Oncology 41: 9-9, 2025. |
|---|
|
|
S2-1. Construction of the local medicine medicine cooperation to work on altogether and efforts ... of the deepening - Higashi-ku, Sapporo-shi area 徳留章1,2,3), 谷口亮央3,4), 菊池健3,5), 藤村拓也3,6), 太田明秀3,7), 鈴木直哉3,4), 辻裕太3,8), 秋山恵里佳3,9) Journal of Japanese Society of Pharmaceutical Oncology 41: 11-11, 2025. |
|---|
|
|
S2-2. New medical cooperation model by the fusion of the area original ICT network and prescription notebook 木本真司 Journal of Japanese Society of Pharmaceutical Oncology 41: 12-12, 2025. |
|---|
|
|
S2-3. Efforts to the cancer screening enlightenment with the drugstore 佐島進 Journal of Japanese Society of Pharmaceutical Oncology 41: 13-13, 2025. |
|---|
|
|
S2-4. About cancer education and the enlightenment activity that a local specialty medical institution cooperation drugstore (cancer) works on 中島美紀 Journal of Japanese Society of Pharmaceutical Oncology 41: 14-14, 2025. |
|---|
|
|
S3-1. After utilizing guidelines, and having known it with in front of case report that let's improve quality, and knew ... CARE; ... 小澤有輝 Journal of Japanese Society of Pharmaceutical Oncology 41: 16-16, 2025. |
|---|
|
|
S3-2. Introduction ... of ... Complete Case Report Writing Course learning how to write case report 藤宮龍祥 Journal of Japanese Society of Pharmaceutical Oncology 41: 17-17, 2025. |
|---|
|
|
S3-3. It is ... for a case in how to write case report - case series utilizing the AI 市村丈典1,2,3) Journal of Japanese Society of Pharmaceutical Oncology 41: 18-18, 2025. |
|---|
|
|
S3-4. What do you do for the intervention to patients with mental disorder by the drugstore pharmacist and the intervention to patients with case report - cancer; ... 前原雅樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 19-19, 2025. |
|---|
|
|
S4-1. A problem of the regimen registration and role of the pharmacist 全田貞幹 Journal of Japanese Society of Pharmaceutical Oncology 41: 21-21, 2025. |
|---|
|
|
S4-2. Fact-finding about the regimen management in the cancer practice cooperation base Hospital, and the like 石井千博 Journal of Japanese Society of Pharmaceutical Oncology 41: 22-22, 2025. |
|---|
|
|
S4-3. Fact-finding of the confirmation of a regimen to affect the cancer medical therapy for the institution except a cancer special hospital and the cancer special hospital item 太田貴洋 Journal of Japanese Society of Pharmaceutical Oncology 41: 23-23, 2025. |
|---|
|
|
S4-4. Clinical studies for the regimen check item commonization 植木大介 Journal of Japanese Society of Pharmaceutical Oncology 41: 24-24, 2025. |
|---|
|
|
S5-1. Efforts for the problem solution of the pharmacist concerned with cancer genomic medicine 櫻井洋臣 Journal of Japanese Society of Pharmaceutical Oncology 41: 26-26, 2025. |
|---|
|
|
S5-2. The basic knowledge that is used by cancer genomic medicine 衛藤智章 Journal of Japanese Society of Pharmaceutical Oncology 41: 27-27, 2025. |
|---|
|
|
S5-3. Role of the health insurance pharmacy in the cancer genomic medicine 角佳亮 Journal of Japanese Society of Pharmaceutical Oncology 41: 28-28, 2025. |
|---|
|
|
S5-4. The role that is demanded from the prospects and the pharmacist of cancer genomic medicine, the precision medicine 土原一哉 Journal of Japanese Society of Pharmaceutical Oncology 41: 29-29, 2025. |
|---|
|
|
S6-1. Glycemic control for patients with cancer at foreign chemotherapy enforcement 大澤勇貴 Journal of Japanese Society of Pharmaceutical Oncology 41: 31-31, 2025. |
|---|
|
|
S6-2. From the position of the pharmacist specialized in - diabetes about the glycemic control of patients with diabetes merger cancer and chic day instruction - 井上岳1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 32-32, 2025. |
|---|
|
|
S6-3. Cancer treatment foreign a drugstore pharmacist, acquiring an authorized qualification, and there being it in the glycemic control of patients with ... cancer, problem ... 吉越彩夏 Journal of Japanese Society of Pharmaceutical Oncology 41: 33-33, 2025. |
|---|
|
|
S6-4. From position of relation - dietitian with patients with diabetes merger cancer - 秋山紘槻 Journal of Japanese Society of Pharmaceutical Oncology 41: 34-34, 2025. |
|---|
|
|
S7-1. It is the purpose explanation of ... book symposium for the patients support of the pharmacist whom area cancer medical care - nobody whom a pharmacist spins leaves behind 野村久祥 Journal of Japanese Society of Pharmaceutical Oncology 41: 36-36, 2025. |
|---|
|
|
S7-2. Role ... as the local hub to snuggle up to the efforts ... patients of the health insurance pharmacy, and to connect 中島美紀 Journal of Japanese Society of Pharmaceutical Oncology 41: 37-37, 2025. |
|---|
|
|
S7-3. I can do it now to become cancer medical care and a social go-between as a pharmacist 沖崎歩1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 38-38, 2025. |
|---|
|
|
S7-4. Began "the cancer education" by the pharmacist; is challenge ... of ... SSOP cancer education WG towards cancer conquest society by the young consciousness change, behavior modification 伊藤剛貴1), 相澤雄介2), 稲田佑亮3), 川田亮4), 国吉央城5), 芝崎由美子6), 武井大輔7), 照屋千津子8), 三村睦美9), 中山季昭7), 佐野元彦10) Journal of Japanese Society of Pharmaceutical Oncology 41: 39-39, 2025. |
|---|
|
|
S7-5. Efforts of the visit drugstore, visit pharmacist who enlarged the field in point of view more highly more 石塚友一 Journal of Japanese Society of Pharmaceutical Oncology 41: 40-40, 2025. |
|---|
|
|
S8-1. It is how to walk ... Central Social Insurance Medical Council ... about the evaluation in Central Social Insurance Medical Council (Central Social Insurance Medical Council) 樋口昇大 Journal of Japanese Society of Pharmaceutical Oncology 41: 42-42, 2025. |
|---|
|
|
S8-2. About JASPO questionnaire utilized by medical service fees revision in 2024 高橋郷1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 43-43, 2025. |
|---|
|
|
S8-3. Efforts ... associated with the foreign cancer medical therapy in duties - Gifu University faculty of medicine hospital where we performed in before medical service fees evaluation 小林亮1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 44-44, 2025. |
|---|
|
|
S8-4. It is ... about the efforts before and after the evaluation new establishment of the dispensing fee in the shop in front of ... Qol drugstore St. Marianna Univ. School of Medicine 福島弘之 Journal of Japanese Society of Pharmaceutical Oncology 41: 45-45, 2025. |
|---|
|
|
S9-1. The revised edition "children, practice guidelines about the fecundity preservation on patients with puberty, juvenile cancer" 歌野智之 Journal of Japanese Society of Pharmaceutical Oncology 41: 47-47, 2025. |
|---|
|
|
S9-2. Between thought and the risks that "want to have children:" Guidance and risk communication of the contraception associated with the administration of pharmaceutical products 日置三紀 Journal of Japanese Society of Pharmaceutical Oncology 41: 48-48, 2025. |
|---|
|
|
S9-3. Viewpoint of the pharmacist to make use of guidelines on the site 湊川紘子 Journal of Japanese Society of Pharmaceutical Oncology 41: 49-49, 2025. |
|---|
|
|
S9-4. With being able to do it as example introduction - drugstore pharmacist from the health insurance pharmacy 久保田愛菜 Journal of Japanese Society of Pharmaceutical Oncology 41: 50-50, 2025. |
|---|
|
|
S10-1. Anticancer medicine and the lesson that caused drug-related pulmonary disorder: We learn from a past example 郷真貴子 Journal of Japanese Society of Pharmaceutical Oncology 41: 52-52, 2025. |
|---|
|
|
S10-2. Early detection and correspondence of drug-related pulmonary disorder (ILD): Specialist in treatment, approach - that the treatment with cooperation - anticancer medicine for respiratory physician, pharmacist risk management is new 加藤晃史 Journal of Japanese Society of Pharmaceutical Oncology 41: 53-53, 2025. |
|---|
|
|
S10-3. Efforts of our hospital for the drug-related pulmonary disorder 立田真也 Journal of Japanese Society of Pharmaceutical Oncology 41: 54-54, 2025. |
|---|
|
|
S10-4. We will think that a pharmacist is able to be able to connect to the treatment from early detection of the drug-related interstitial pneumonia through a case 原田知彦 Journal of Japanese Society of Pharmaceutical Oncology 41: 55-55, 2025. |
|---|
|
|
S11-1. Apply cooperation, the digital technology with the health insurance pharmacy using patients information in it; and "what do send how? " 高山俊輔 Journal of Japanese Society of Pharmaceutical Oncology 41: 57-57, 2025. |
|---|
|
|
S11-2. We fly, and can the health insurance pharmacy be beyond "a cliff of 2025" of DX? 本田雅志 Journal of Japanese Society of Pharmaceutical Oncology 41: 58-58, 2025. |
|---|
|
|
S11-3. It inflects with the analysis of the follow-up example after the formulations by the ICT 山崎友樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 59-59, 2025. |
|---|
|
|
S11-4. Approach about PHR of Ministry of Economy, Trade and Industry 山中涼佑 Journal of Japanese Society of Pharmaceutical Oncology 41: 60-60, 2025. |
|---|
|
|
S12-1. It is ... from the position of the specialist in thing - cancer practice that is necessary in Advanced Care Planning (ACP) for the patients whom ability for decision making decreased 千島隆司1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 62-62, 2025. |
|---|
|
|
S12-2. The ACP for the patients whom the ability for decision making decreased: What can you do for hospital pharmacist? 奥苑朱加 Journal of Japanese Society of Pharmaceutical Oncology 41: 63-63, 2025. |
|---|
|
|
S12-3. Relation to the ACP in the drugstore pharmacist 後藤彬宏 Journal of Japanese Society of Pharmaceutical Oncology 41: 64-64, 2025. |
|---|
|
|
S12-4. Than the position of the ACP - psychology person for patients having low ability for decision making - 塚野佳世子 Journal of Japanese Society of Pharmaceutical Oncology 41: 65-65, 2025. |
|---|
|
|
S13-1. Cancer practice of childhood cancer and the AYA generation 荒川歩 Journal of Japanese Society of Pharmaceutical Oncology 41: 67-67, 2025. |
|---|
|
|
S13-2. Relation of the pharmacist in the pediatric special hospital 歌野智之 Journal of Japanese Society of Pharmaceutical Oncology 41: 68-68, 2025. |
|---|
|
|
S13-3. Relation of the health insurance pharmacy pharmacist for patients with childhood cancer 野々村磨つ1), 荒川歩2), 歌野智之3), 餅原弘樹4) Journal of Japanese Society of Pharmaceutical Oncology 41: 69-69, 2025. |
|---|
|
|
S13-4. Relation of the home care support medical office pharmacist for patients with AYA generation cancer 餅原弘樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 70-70, 2025. |
|---|
|
|
S14-1. Trouble and invention - municipal hospital edition ... of the setup of the cancer pharmacist outpatient department 杉山弘樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 72-72, 2025. |
|---|
|
|
S14-2. An effect and problem by the rebuilding of the pharmacist outpatient department 葉山達也 Journal of Japanese Society of Pharmaceutical Oncology 41: 73-73, 2025. |
|---|
|
|
S14-3. We think about the further possibility of the sustainable pharmacist outpatient 高田慎也 Journal of Japanese Society of Pharmaceutical Oncology 41: 74-74, 2025. |
|---|
|
|
S14-4. It is ... from the viewpoint of signpost ... physician of the cancer pharmacist outpatient department 勝俣範之 Journal of Japanese Society of Pharmaceutical Oncology 41: 75-75, 2025. |
|---|
|
|
S15-1. The useful patients support that the telephone follow-up is possible easily! 坂田幸雄 Journal of Japanese Society of Pharmaceutical Oncology 41: 77-77, 2025. |
|---|
|
|
S15-2. The efforts of the medication follow-up with the telephone in a in drugstore Soen station square store and future problem 糸井陽介1), 坂田幸雄2), 桂英之3), 鈴木直哉4), 安部圭紀5), 田橋美佳6) Journal of Japanese Society of Pharmaceutical Oncology 41: 78-78, 2025. |
|---|
|
|
S15-3. Deepening of the medicine medicine cooperation utilizing the telephone follow-up 鈴木直哉 Journal of Japanese Society of Pharmaceutical Oncology 41: 79-79, 2025. |
|---|
|
|
S15-4. The application is useful patients support with the merit of the strongest! 桂英之 Journal of Japanese Society of Pharmaceutical Oncology 41: 80-80, 2025. |
|---|
|
|
S15-5. Are patients busy with the medical person too, too? The application utilization art which is usable in such a case 安部圭紀 Journal of Japanese Society of Pharmaceutical Oncology 41: 81-81, 2025. |
|---|
|
|
S15-6. Very attentive? Application utilization technique at the drugstore 田橋美佳 Journal of Japanese Society of Pharmaceutical Oncology 41: 82-82, 2025. |
|---|
|
|
S16-1. The standard cord in the regimen: A way of thinking and specific example 佐藤弘康 Journal of Japanese Society of Pharmaceutical Oncology 41: 84-84, 2025. |
|---|
|
|
S16-2. Problem of the regimen order ring system in the healthcare setting 山口健太郎 Journal of Japanese Society of Pharmaceutical Oncology 41: 85-85, 2025. |
|---|
|
|
S16-3. Standardization and regimen information in the study using RWD 高田敦史 Journal of Japanese Society of Pharmaceutical Oncology 41: 86-86, 2025. |
|---|
|
|
S16-4. Some viewpoints to think about regimen standardization 小枝伸行 Journal of Japanese Society of Pharmaceutical Oncology 41: 87-87, 2025. |
|---|
|
|
S17-1. It is ... about medicine medicine cooperation of efforts and problem - cancer medical therapy of the job area group combination in Tokyo 清水久範 Journal of Japanese Society of Pharmaceutical Oncology 41: 89-89, 2025. |
|---|
|
|
S17-2. Pharmacist collaboration has transformed the community! - The next stage for pharmacists - 野田政充 Journal of Japanese Society of Pharmaceutical Oncology 41: 90-90, 2025. |
|---|
|
|
S17-3. Our hospital doesn't have a department like XX! Turning weaknesses into strengths: Collaboration between hospital pharmacists and pharmacy pharmacists - An example of sick day care for patients with adrenal insufficiency - 新井隆広 Journal of Japanese Society of Pharmaceutical Oncology 41: 91-91, 2025. |
|---|
|
|
S17-4. To enable medicine medicine cooperation - Lenvatinib long-term use that let's prevent the patients loss by the side effect, and started from Kurume University; ... 津村紗代 Journal of Japanese Society of Pharmaceutical Oncology 41: 92-92, 2025. |
|---|
|
|
S17-5. Viewpoint ... from medicine medicine cooperation - specialty medical institution cooperation drugstore through the telephone follow-up to the Lenvatinib remedy patients 馬渡つかさ Journal of Japanese Society of Pharmaceutical Oncology 41: 93-93, 2025. |
|---|
|
|
S18-1. Career planning based on practical training and multi-institutional collaborative research experiences and learning 高橋佳織 Journal of Japanese Society of Pharmaceutical Oncology 41: 95-95, 2025. |
|---|
|
|
S18-2. Way of working of the drugstore pharmacist judging from the authorization of the specialized medical institution cooperation drugstore 大熊祐美 Journal of Japanese Society of Pharmaceutical Oncology 41: 96-96, 2025. |
|---|
|
|
S18-3. Efforts of the sustainable way of working and carrier support in the municipal hospital 橋口宏司 Journal of Japanese Society of Pharmaceutical Oncology 41: 97-97, 2025. |
|---|
|
|
S18-4. To walk the life that seems to be carrier design strategy - oneself of the pharmacist living in the VUCA era; ... 流石学1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 98-98, 2025. |
|---|
|
|
S19-1. Dermatopathy (the general remarks) in cancer treatment 縄田修一1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 100-100, 2025. |
|---|
|
|
S19-2. Drying and skin care of the skin 稲葉さやか Journal of Japanese Society of Pharmaceutical Oncology 41: 101-101, 2025. |
|---|
|
|
S19-3. Introduction and practice ... of dermatopathy management - PBPM of the antiEGFR antibody medicine 森田一 Journal of Japanese Society of Pharmaceutical Oncology 41: 102-102, 2025. |
|---|
|
|
S19-4. ... which thinks about skin care out of ... "seven skin troubles" as patients can live like oneself 藤田あゆみ Journal of Japanese Society of Pharmaceutical Oncology 41: 103-103, 2025. |
|---|
|
|
S20-1. The purpose explanation of this symposium and gustatory point of view 高山俊輔 Journal of Japanese Society of Pharmaceutical Oncology 41: 105-105, 2025. |
|---|
|
|
S20-2. Which do you choose? It is flavor and anosmia ... of ... nutrient preparation with the nutrient preparation which the user buys 森ひろみ Journal of Japanese Society of Pharmaceutical Oncology 41: 106-106, 2025. |
|---|
|
|
S20-3. We think about the energy production of patients with cancer 滝澤康志 Journal of Japanese Society of Pharmaceutical Oncology 41: 107-107, 2025. |
|---|
|
|
S20-4. The multi-type of job cooperation, example introduction from position of the hospital pharmacist 大登剛 Journal of Japanese Society of Pharmaceutical Oncology 41: 108-108, 2025. |
|---|
|
|
S20-5. Information cooperation about the nourishment from the viewpoint of the health insurance pharmacy pharmacist 立澤明 Journal of Japanese Society of Pharmaceutical Oncology 41: 109-109, 2025. |
|---|
|
|
S21-1. Summary of authorization, the specialized pharmacist system in Japanese clinical tumor Pharmaceutical Society 鈴木真也 Journal of Japanese Society of Pharmaceutical Oncology 41: 111-111, 2025. |
|---|
|
|
S21-2. The review of the pharmaceutical intervention example and evaluation of the interview 内池明博 Journal of Japanese Society of Pharmaceutical Oncology 41: 112-112, 2025. |
|---|
|
|
S21-3. Introduction of the cancer practice hospital cooperation training 縄田修一1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 113-113, 2025. |
|---|
|
|
S21-4. Point of the cancer practice hospital cooperation training wanting you to know it now 衛藤智章 Journal of Japanese Society of Pharmaceutical Oncology 41: 114-114, 2025. |
|---|
|
|
S21-5. Than the position of thing - drugstore pharmacist who want to report as a specialized pharmacist ... 菅美佳 Journal of Japanese Society of Pharmaceutical Oncology 41: 115-115, 2025. |
|---|
|
|
S22-1. PRO utilization in the clinical adverse event evaluation to think about from clinical studies 川口崇1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 117-117, 2025. |
|---|
|
|
S22-2. We try to think about the evaluation method of the adverse event some other time 山口拓洋 Journal of Japanese Society of Pharmaceutical Oncology 41: 118-118, 2025. |
|---|
|
|
S22-3. Comprehensive approach ... which reflected reconsideration ... patients viewpoint of the chemotherapy-induced retching vomiting management 横川貴志 Journal of Japanese Society of Pharmaceutical Oncology 41: 119-119, 2025. |
|---|
|
|
S22-4. The current situation and problem of the adverse event evaluation of irAE in the pharmacist 臼井浩明 Journal of Japanese Society of Pharmaceutical Oncology 41: 120-120, 2025. |
|---|
|
|
S22-5. Adverse event evaluation in the childhood cancer 早瀬朋美 Journal of Japanese Society of Pharmaceutical Oncology 41: 121-121, 2025. |
|---|
|
|
S23-1. Pharmacist education that ... pharmacist opens up efforts of the overseas deployment training and the overseas training for bread of Japan, contribution ... to cancer medical care 森本麻友 Journal of Japanese Society of Pharmaceutical Oncology 41: 123-123, 2025. |
|---|
|
|
S23-2. We think about present of the foreign cancer chemotherapy of ... Japan and future ... through the clinical duties of the American medical care, pharmacy education, pharmacist 大畑紘一 Journal of Japanese Society of Pharmaceutical Oncology 41: 124-124, 2025. |
|---|
|
|
S23-3. Pharmacist resident education of America, having learned from the relation of the pharmacist to a clinical study, the future and the prospects of Japanese cancer special hospital pharmacists 中村真穂 Journal of Japanese Society of Pharmaceutical Oncology 41: 125-125, 2025. |
|---|
|
|
S23-4. It is ... about specialty and the mind of difference between Japan and American pharmacist that we learned through the overseas training and ... pharmacist thinking about the future 山田早 Journal of Japanese Society of Pharmaceutical Oncology 41: 126-126, 2025. |
|---|
|
|
S23-5. Expectation to the importance of the international exchange and this business Lisa Modelevsky Journal of Japanese Society of Pharmaceutical Oncology 41: 127-127, 2025. |
|---|
|
|
S23-6. Expect it of a coming overseas deployment training person 久松大祐 Journal of Japanese Society of Pharmaceutical Oncology 41: 128-128, 2025. |
|---|
|
|
S24-1. One or ... to use the time when it became vacant by the efficiency of three role ... of the pharmacist in the cancer medical care that we saw from a physician vs. thing duties for how 狭間研至 Journal of Japanese Society of Pharmaceutical Oncology 41: 130-130, 2025. |
|---|
|
|
S24-2. The thing which we saw by formulations robot introduction 高橋俊明 Journal of Japanese Society of Pharmaceutical Oncology 41: 131-131, 2025. |
|---|
|
|
S24-3. The need of the interpersonal duties promotion at the health insurance pharmacy in foreign cancer treatment 中村俊貴 Journal of Japanese Society of Pharmaceutical Oncology 41: 132-132, 2025. |
|---|
|
|
S24-4. The future of the cancer medical care that the AI deployment type formulations robot brings 渡部正之 Journal of Japanese Society of Pharmaceutical Oncology 41: 133-133, 2025. |
|---|
|
|
BP-1. Patients, hospital, measure for approach and improvement to the local drugstore in recognition that a specialized medical institution cooperation drugstore takes 三星勇輝 Journal of Japanese Society of Pharmaceutical Oncology 41: 135-135, 2025. |
|---|
|
|
BP-2. Examination about the pharmaceutical and medical economic benefit of the specialized medical institution cooperation drugstore (cancer) 植竹友輔 Journal of Japanese Society of Pharmaceutical Oncology 41: 136-136, 2025. |
|---|
|
|
OA1-01. Search of the factor having poor symptom control of the anticholinergic drug single prophylaxis for the irinotecan-induced Colin symptom 渡辺拓也1), 齋藤佳敬2), 武隈洋1), 清水康3), 木下一郎3), 小松嘉人4), 菅原満1,5) Journal of Japanese Society of Pharmaceutical Oncology 41: 137-137, 2025. |
|---|
|
|
OA1-02. We look at the rear about the effect that difference in BMI gives the blood toxicity by the Carboplatin in the gynecologic cancer domain and examine a mark 尾花輝樹1,2), 藤本伸一郎1), 藤原季美子1), 竹上学1), 長井紀章2), 西田升三2), 椿正寛3) Journal of Japanese Society of Pharmaceutical Oncology 41: 138-138, 2025. |
|---|
|
|
OA1-03. Factorial experiments of docetaxel-induced edema in patients with non-small cell lung cancer 山下慎介1,2), 齋藤佳敬3), 今井俊吾4,5), 柏木仁4), 佐藤夕紀4), 梨本俊亮4), 榊原純6), 清水康7), 木下一郎7), 武隈洋2), 菅原満2,4) Journal of Japanese Society of Pharmaceutical Oncology 41: 139-139, 2025. |
|---|
|
|
OA1-04. Safe evaluation by the fluid replacement method change of the cisplatin regimen for patients with uterine cervix cancer 丸田愛美1), 福田真弓1), 齋藤圭佑1), 戸津舞衣子1), 櫻井学1), 佐治晴哉2) Journal of Japanese Society of Pharmaceutical Oncology 41: 140-140, 2025. |
|---|
|
|
OA1-05. Effect to give the expression situation and effect of treatment of delayed immune-mediated adverse event (irAE) by immune checkpoint inhibitor (ICI) 岩田理沙, 熊倉康郎, 中村美菜, 溝口博之, 池末裕明 Journal of Japanese Society of Pharmaceutical Oncology 41: 141-141, 2025. |
|---|
|
|
OA1-06. Observational study about the pneumocystis pneumonia (PCP) prevention in patients with perioperative breast cancer that showed lymphocytopenia 中村朱里1), 馬場楓1), 楠原佳那子1), 加藤州1), 内藤陽一2,3,4), 松原伸晃2), 細野亜古2,5), 近藤千紘2), 原野謙一2,4), 中島裕理2,3,4), 船坂知華子2,4), 冲中敬二6), 川崎敏克1), 向原徹2) Journal of Japanese Society of Pharmaceutical Oncology 41: 142-142, 2025. |
|---|
|
|
OA1-07. Examination of the usefulness of the comprehensive elderly people with patients with old metastasis-related pancreatic cancer usability test based on the G8 screening by the pharmacist in the cancer chemotherapy 苅田柾人1), 中村大学1,3), 堀雅之1), 今井友香莉1), 植家晴紀1), 小林紀香1), 首藤真里1), 西垣和香1), 堀田祐志1,3), 近藤勝弘2,3), 日比陽子1,3) Journal of Japanese Society of Pharmaceutical Oncology 41: 143-143, 2025. |
|---|
|
|
OA1-08. Experience report for retching, vomiting of the Zolbetuximab in our hospital 近藤優樹1), 江尻将之1), 前田哲志1), 安藤究1), 松本俊彦2), 神田武生3), 福崎美代子4), 土井幸穂4), 内田千絵4), 石川文栄4), 後藤健志1) Journal of Japanese Society of Pharmaceutical Oncology 41: 144-144, 2025. |
|---|
|
|
OA1-09. Learning needs investigation of the multi-type of job medical care person for the development of the cancer survivor ship education teaching materials 牧野あずみ1,14), 土屋雅美2,14), 青儀健二郎3,14), 高橋都4,14), 佐々木治一郎5,14), 押川勝太郎6,14), 桜井なおみ7,14), 久村和穂8,14), 山本瀬奈9,14), 井沢知子10,14), 井上佳代11,14), 高橋孝郎12,14), 柴田喜幸13) Journal of Japanese Society of Pharmaceutical Oncology 41: 145-145, 2025. |
|---|
|
|
OA2-01. The multicenter retrospective study that tested an antiemesis effect of the aprepitant combination on biliary cancer gemcitabine + cisplatin therapy 藤林遼1), 梅原健吾2), 平手大輔3), 小岡亜矢3), 高崎修一4), 下口谷貴5), 日下部鮎子6), 畠山智明7), 長谷川由季8), 清水敦也9), 太田明秀10), 前田健太11), 渡邉大毅12), 高田慎也2), 山岸佳代2), 藤川幸司13), 橋下浩紀2) Journal of Japanese Society of Pharmaceutical Oncology 41: 146-146, 2025. |
|---|
|
|
OA2-02. Stratified analysis aiming at improvement in predictive precision of the chemotherapy toxic predictive tool for patients with old cancer 内山将伸, 中野貴文, 山科卓也, 松尾宏一 Journal of Japanese Society of Pharmaceutical Oncology 41: 147-147, 2025. |
|---|
|
|
OA2-03. The change of the serum creatinine during Abemaciclib administration may affect the dose adjustment of the combination drug 梅原健吾1), 高田慎也1), 齋藤佳敬2), 斉藤諒1), 山岸佳代1), 小金澤千夏3), 太刀川花恵3), 敷島果林3), 山本貢3), 冨岡伸元3), 渡邊健一3), 橋下浩紀1) Journal of Japanese Society of Pharmaceutical Oncology 41: 148-148, 2025. |
|---|
|
|
OA2-04. Examination about the proper use of the G-CSF preparation based on the risk factor analysis of the FN onset by the TC therapy in gynecologic cancer 齋藤冬都希, 遠藤征裕, 齋藤雅隆, 佐々木良 Journal of Japanese Society of Pharmaceutical Oncology 41: 149-149, 2025. |
|---|
|
|
OA2-05. Search of the factor developing neutropenia by nanoliposomal type irinotecan /FU/LV in the unresectable pancreatic cancer 竹田健志, 田中佐季, 中村さやか, 野崎圭佑, 角川幸男, 長谷川聡司, 高木麻里 Journal of Japanese Society of Pharmaceutical Oncology 41: 150-150, 2025. |
|---|
|
|
OA3-01. Multicenter study about the risk factor of optimum doses and the neutropenia of the nab-PTX+GEM therapy in patients with old progress recurrence pancreatic cancer 佐藤優弥1), 田口伸1), 和地徹1), 鐙屋舞子2), 相場悠樹3), 遠藤征裕4), 伊藤郁恵4), 酒井良隆5), 梅田慎也6), 大原正之7), 佐藤家恒8), 高橋久樹9) Journal of Japanese Society of Pharmaceutical Oncology 41: 151-151, 2025. |
|---|
|
|
OA3-02. Search of the onset actual situation of the tumor lysis syndrome in the solid tumor and the risk factor 近藤勝弘1,2), 堀田祐志2,3), 井口祐美子1), 小松弘和4,5), 日比陽子2,3) Journal of Japanese Society of Pharmaceutical Oncology 41: 152-152, 2025. |
|---|
|
|
OA3-03. Efforts to cancer medical therapy side effect evaluation sheet (tracing report) unionization for the cancer medical care elimination 曽根敦子1), 玉井香菜子1), 村山晴夫2), 稲野寛3), 高橋郷4), 佐藤美咲5), 根本隆一郎6), 菅原充広7), 鈴木優司1) Journal of Japanese Society of Pharmaceutical Oncology 41: 153-153, 2025. |
|---|
|
|
OA3-04. Questionary survey to expand the workshop of cooperation enhancement addition institution standard requirements 河野慎吾, 小林一男, 中野泰寛, 瀧口友美, 清水久範, 山口正和 Journal of Japanese Society of Pharmaceutical Oncology 41: 154-154, 2025. |
|---|
|
|
OA3-05. The effect that pharmacist duties in the foreign cancer chemotherapy give to a relative dose intensity 岡崎秀太, 永井大地, 小森由理子, 高橋一栄 Journal of Japanese Society of Pharmaceutical Oncology 41: 155-155, 2025. |
|---|
|
|
O2-01. About the side effect of butylscopolamine bromide coinfusion method measures of the irinotecan-induced Colin symptom in our hospital 矢羽々俊1), 黒田祥嗣1), 信田磨尭1), 谷地真亜子1), 鎌田裕也1), 柵山敬司1), 佐々木健汰2) Journal of Japanese Society of Pharmaceutical Oncology 41: 156-156, 2025. |
|---|
|
|
O2-02. "Patients all cases, the efforts which realized intervention" every time in the foreign chemotherapy room 萩谷瑞紀, 小宮山崇仁, 小田部咲樹, 花香淳一 Journal of Japanese Society of Pharmaceutical Oncology 41: 157-157, 2025. |
|---|
|
|
O2-03. Search of the onset predictor of irAE by the Atezolizumab 井上陽1), 小田部航大1), 山口陽也1), 東湧真2), 吉成宏顕2), 大橋勇紀3), 野村彩衣1), 高崎新也1) Journal of Japanese Society of Pharmaceutical Oncology 41: 158-158, 2025. |
|---|
|
|
O2-04. Evaluation of dexamethasone prophylaxis to reduce adverse events associated with enfortumab vedotin administration 石井紗英子1), 末廣直哉1), 長島彩乃1), 櫻井洋臣1), 村松博1), 河添仁1,2,3), 大谷壽一1,2,3) Journal of Japanese Society of Pharmaceutical Oncology 41: 159-159, 2025. |
|---|
|
|
O2-05. Establishment of the pharmacist outpatient department for the cancer medical therapy system full addition acquisition and examination about the usefulness 吉川直美1), 佐藤信恵1), 岩本大紀1), 佐藤美咲1), 橋本章吾1), 鈴村史帆1), 石渡智子1), 川邊元子1), 片山卓爾2), 旗手和彦3), 柳原奈歩4), 平島奈奈子4), 山本美紀5), 佐藤真希5), 森達也1) Journal of Japanese Society of Pharmaceutical Oncology 41: 160-160, 2025. |
|---|
|
|
O2-06. Change of a polarization state of the macrophage in the ascitic fluid of patients with pancreatic cancer before and after the CART enforcement and the immune-mediated factor 小堀宅郎1), 勝山優衣1), 田中千都2), 浦嶋庸子1), 山村智代2), 堀田紀久子1), 高垣伸匡3), 小畑友紀雄1) Journal of Japanese Society of Pharmaceutical Oncology 41: 161-161, 2025. |
|---|
|
|
O2-07. We see the rear evaluating the effect that the difference in administration method in Bev+TAS-102 gives the expression of the survival period of patients with colon cancer and the adverse event and study a mark 安藤洋介1), 折戸花帆2), 松岡宏3), 水野智博1), 勝野秀稔4), 守瀬善一4), 堀口明彦5), 林高弘1,2), 山田成樹1) Journal of Japanese Society of Pharmaceutical Oncology 41: 162-162, 2025. |
|---|
|
|
O2-08. Hepatitis B measures support PBPM for the inpatient 原口智彦, 原田周平, 入江貞治, 井上知哉, 馬場麗奈, 荒木正義, 池上沙織, 丸山真理子, 隈部法子, 宮上桐豪, 藤田靖之, 池田能利子 Journal of Japanese Society of Pharmaceutical Oncology 41: 163-163, 2025. |
|---|
|
|
O2-09. The association of IRRs expression and in front of adrenal cortical hormone medicine doses after the Obinutuzumab initial administration: Multi-organization combination past starting point cohort study 大坪達弥1), 山本和宏2), 松本早織3), 伊藤佳織4,5), 佐々侑寿香6), 冨島公介7), 土手賢史8), 槙原克也9), 若杉吉宣10), 光家勉11), 山極恒平12), 佐藤和生13), 長谷川広樹14), 魚嶋伸彦15), 北廣優実16), 友金幹視1) Journal of Japanese Society of Pharmaceutical Oncology 41: 164-164, 2025. |
|---|
|
|
O3-01. The effectiveness of dexamethasone shortening in the olanzapine + palonosetron + aprepitant combination therapy for patients who received AC/EC therapy 山本泰大, 福岡智宏, 林宏紀, 青木さやか, 出口裕子 Journal of Japanese Society of Pharmaceutical Oncology 41: 165-165, 2025. |
|---|
|
|
O3-02. About a tendency of the trifluridine Tipiracil hydrochloride + bevacizumab combination therapy to onset of retching and the countermeasure 山下慎司, 光家勉, 中村緑, 上田豊実 Journal of Japanese Society of Pharmaceutical Oncology 41: 166-166, 2025. |
|---|
|
|
O3-03. The effect that the minocycline administration in antiEGFR antibody medicine-treated patients gives 渡邊太朗1,2), 相良英憲2), 古川誠之1), 名和田幸介1), 有間幹人1), 手嶋ひさ子1) Journal of Japanese Society of Pharmaceutical Oncology 41: 167-167, 2025. |
|---|
|
|
O3-04. The use situation investigation of the naldemedine for the prevention of opioid-induced constipation, retching vomiting 田中亮, 森井悠介, 新居万莉, 森本智, 松井駿亮, 大河万顕, 瀬名波宏昌, 下村一徳 Journal of Japanese Society of Pharmaceutical Oncology 41: 168-168, 2025. |
|---|
|
|
O3-05. The establishment situation of the pharmacist outpatient department in the foreign cancer chemotherapy of our hospital and the evaluation 小山加奈世, 阿部史誉, 早川太朗 Journal of Japanese Society of Pharmaceutical Oncology 41: 169-169, 2025. |
|---|
|
|
O3-06. The effectiveness of Dell isomaltose second iron for anemia with the digestive organ cancer chemotherapy: Single institution observational, prospective study (the first report) 相楽勇人1), 佐々木勇人4), 石塚純平2), 櫻庭一馬5), 高橋研太郎2), 進藤吉明2,3), 田中雄一2) Journal of Japanese Society of Pharmaceutical Oncology 41: 170-170, 2025. |
|---|
|
|
O4-01. Comparison of the effectiveness by the treatment order of mFOLFIRINOX therapy and the GEM+nab-PTX therapy in patients with unresectable pancreatic cancer 住井遥1,2), 高田遼1), 牧賢利1), 高橋洋子1), 佐藤聡2), 濱岡照隆1) Journal of Japanese Society of Pharmaceutical Oncology 41: 171-171, 2025. |
|---|
|
|
O4-02. Usefulness and problems of the cancer chemotherapy side effect management application 塚川麻利子1), 溝口明子1), 市川瑞季1), 辻茉莉香1), 松浦千裕1), 村山三佳1), 田橋美佳1,2), 浅倉淳子1,3), 加藤美紀1,4), 五十嵐文1), 五十嵐俊1), 山本郁生1) Journal of Japanese Society of Pharmaceutical Oncology 41: 172-172, 2025. |
|---|
|
|
O4-03. Examination of the validity of subcutaneous administration of Pertuzumab, Trastuzumab, and Vorhyaluronidase Alfa using a syringe pump 伊藤剛貴1), 下山加奈恵1), 平野航1), 男鹿宏和1), 高橋未歩2), 石原早希子3), 木村直也1) Journal of Japanese Society of Pharmaceutical Oncology 41: 173-173, 2025. |
|---|
|
|
O4-04. About the examination situation and prognosis after the checkpoint inhibitor cancellation in the municipal Ashiya Hospital of immunity 橋本百世1), 仁木一順2), 見田秋与志1) Journal of Japanese Society of Pharmaceutical Oncology 41: 174-174, 2025. |
|---|
|
|
O4-05. Efforts of "the measurement and the inspection of an attitude survey before and after the cancer-related class attendance for drugstore pharmacists and the education effect" 和田憲周1), 鹿嶋隆行1), 宮川道英1,2), 谷森佳弘1), 伊津田知樹1), 浦嶋庸子1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 175-175, 2025. |
|---|
|
|
O4-06. The effect that fever in the Dabrafenib Trametinib combination therapy gives in a dose intensity on thyroid cancer 塩谷純子1), 正木千恵2), 杉野公則2), 嘉山吉志維1), 寺澤友基子1), 横塚智1), 鈴木章史2), 北川亘2), 伊藤公一2) Journal of Japanese Society of Pharmaceutical Oncology 41: 176-176, 2025. |
|---|
|
|
O5-01. Fact-finding of the cancer treatment-related cardiovascular disease onset and the treatment outcome 青木楓佳, 竹森飛翔, 渋谷悠真 Journal of Japanese Society of Pharmaceutical Oncology 41: 177-177, 2025. |
|---|
|
|
O5-02. Efforts of the prescription support for the antiemetic drug of the highly emetic risk anticancer agent of our hospital 高木明子, 牛丸星, 高本裕子, 長谷川優里香, 古川莉彩, 正木拓也, 長島裕樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 178-178, 2025. |
|---|
|
|
O5-03. Effect of the immune checkpoint inhibitor on onset situation of the eruption by the ST medical mixture 本間崇正1), 前田珠希2), 鳥居昌太1), 江崎秀樹1), 榊原隆志1), 滝本典夫1) Journal of Japanese Society of Pharmaceutical Oncology 41: 179-179, 2025. |
|---|
|
|
O5-04. The use of anamorelin situation to patients with non-small cell lung cancer in our hospital 相場悠樹, 佐藤浩保 Journal of Japanese Society of Pharmaceutical Oncology 41: 180-180, 2025. |
|---|
|
|
O5-05. About a relationship of Atezolizumab therapy and the dermatopathy 濱武清範1), 松田ちひろ1), 奥村有香1), 野間敏也1), 橋本仁美1), 奥村優介1), 兼行佑奈1), 松本弘誠1), 仲忠士1), 美和孝之1), 小島一晃1), 北英夫2) Journal of Japanese Society of Pharmaceutical Oncology 41: 181-181, 2025. |
|---|
|
|
O5-06. Examination of the risk factor about neutropenia after the FOLFOX and FOLFIRI therapy enforcement 安部博宣, 白岩健, 衛藤大輝, 田中遼大, 龍田涼佑, 伊東弘樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 182-182, 2025. |
|---|
|
|
O5-07. A case which contributed to improvement in adherence of the supportive care by at-home visit drug control instruction for polypharmacy during foreign cancer chemotherapy 地引勝 Journal of Japanese Society of Pharmaceutical Oncology 41: 183-183, 2025. |
|---|
|
|
O5-08. It is one consideration of effectively utilizing it medical resources in the anticancer medicine 長尾嘉真1), 小川千晶1), 石嶋麗1), 赤岩愛記1), 大栗宝子1), 大塚健太郎1), 長山佳之1), 今村有那1), 須河恭敬2), 軍司剛宏1) Journal of Japanese Society of Pharmaceutical Oncology 41: 184-184, 2025. |
|---|
|
|
O5-09. Review of the regimen management method accompanied with the electronic medical chart renovation 田中晃佑, 熊本みな子, 西原夢乃, 木村雄太, 高田慎也, 山岸佳代, 橋下浩紀 Journal of Japanese Society of Pharmaceutical Oncology 41: 185-185, 2025. |
|---|
|
|
O6-01. One case of patients with breast cancer that caused hypersensitivity reaction in paclitaxel and docetaxel 小中千広, 藤本亜弓, 高木裕介, 山崎直樹, 中尾將彦, 森宏幸 Journal of Japanese Society of Pharmaceutical Oncology 41: 186-186, 2025. |
|---|
|
|
O6-02. The continuation situation of the Abemaciclib remedy patients in the Ogaki Tokushukai Hospital, the side effect situation and the intervention situation of the pharmacist 遠藤秀竜, 加藤貴由, 中島彩子, 見尾谷昇, 山崎崇 Journal of Japanese Society of Pharmaceutical Oncology 41: 187-187, 2025. |
|---|
|
|
O6-03. One case that improved pain by opioid switching in consideration of drug interaction 守田和憲1), 高橋周平1), 山下園加1), 田上治美1), 森北辰馬2) Journal of Japanese Society of Pharmaceutical Oncology 41: 188-188, 2025. |
|---|
|
|
O6-04. One case of rectal cancer MSI-High which tardive irAE1 type diabetes developed in after the treatment with immune checkpoint inhibitor cancellation 柏木直人, 堀之内藍, 小泉綾乃, 田中敏 Journal of Japanese Society of Pharmaceutical Oncology 41: 189-189, 2025. |
|---|
|
|
O6-05. A clinical course and histories of treatment of a case which developed febrile neutropenia and pneumocystis pneumonia during colon cancer chemotherapy 牧賢利1), 住井遥1), 藤原未稀1), 高田遼1), 野村直幸1), 高橋洋子1), 妹尾賢2), 齊藤誠司3), 濱岡照隆1) Journal of Japanese Society of Pharmaceutical Oncology 41: 190-190, 2025. |
|---|
|
|
O6-06. Two cases that supported with the division formulations in consideration of excessive quantity filling with the supply stop of the hippopotamus diTaki cell 伊勢崎竜也1), 田中慎1), 作間航志朗1), 舟越亮寛1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 191-191, 2025. |
|---|
|
|
O6-07. Stand on the example of the patients who developed in for inappetence during ... Abemaciclib therapy about efforts of the reporting to local other drugstores; and ... 藤井康之 Journal of Japanese Society of Pharmaceutical Oncology 41: 192-192, 2025. |
|---|
|
|
O6-08. 1 case that a health insurance pharmacy pharmacist was able to intervene in for high blood pressure with the cancer chemotherapy by the information sharing using the tracing report early 野村太嗣, 飯島郷美, 吉川佳那, 阪本真季, 小林久仁 Journal of Japanese Society of Pharmaceutical Oncology 41: 193-193, 2025. |
|---|
|
|
O6-09. Case using bath articles magnesium-containing for hypomagnesemia with the antiEGFR antibody medicine administration 米良千春 Journal of Japanese Society of Pharmaceutical Oncology 41: 194-194, 2025. |
|---|
|
|
O7-01. A case that long-term progression-free survival by the Cabozantinib was obtained for metastatic renal-cell carcinoma: Change of the blood level 丸山真一1,2), 加藤大2), 石田勝3), 菅野浩1) Journal of Japanese Society of Pharmaceutical Oncology 41: 195-195, 2025. |
|---|
|
|
O7-02. Three patients who presented with type I diabetes mellitus with an immune checkpoint inhibitor 荒毛祐吏美1), 守田和憲1), 田上治美1), 神宮直樹2), 保田祐子2), 一門和哉2), 三井士和3), 森北辰馬3), 小田尚伸3), 坂本快郎3), 松尾靖人4), 星乃明彦4) Journal of Japanese Society of Pharmaceutical Oncology 41: 196-196, 2025. |
|---|
|
|
O7-03. Head and neck aluminum Knox treatment case in our hospital 井口麻美, 神庭楓, 殿村直也, 宮澤真帆, 山口智 Journal of Japanese Society of Pharmaceutical Oncology 41: 197-197, 2025. |
|---|
|
|
O7-04. A case in which severe back pain during Onivyde(R) administration led to a change in regimen 塚本名奈子, 田中麻理子, 辰己晃造, 本田富得 Journal of Japanese Society of Pharmaceutical Oncology 41: 198-198, 2025. |
|---|
|
|
O7-05. One case that presented Abemaciclib and erythema multiforme of the fulvestrant combination therapy 沢仁美1,3), 土居貞幸2), 中村暢彦4) Journal of Japanese Society of Pharmaceutical Oncology 41: 199-199, 2025. |
|---|
|
|
O7-06. Efforts to the in-hospital system construction for the Zolbetuximab introduction 芦崎雅之1), 岩村千晴2), 小野寺馨3), 奥田博介3), 平田力1) Journal of Japanese Society of Pharmaceutical Oncology 41: 200-200, 2025. |
|---|
|
|
O8-01. Introduction effect of the hypodermic injection preparation in patients with HER2-positive breast cancer 小枝伸行1), 小川充恵2) Journal of Japanese Society of Pharmaceutical Oncology 41: 201-201, 2025. |
|---|
|
|
O8-02. A case which accepted the change of the platelet accompanied with the change of the anticancer agent regimen in patients with bladder cancer 渡邊亜矢子1,2), 小川祐3), 佐伯美沙1,4), 永田卓也1,5), 森田將6), 柏原由佳1,5), 百賢二1) Journal of Japanese Society of Pharmaceutical Oncology 41: 202-202, 2025. |
|---|
|
|
O8-03. 1 case that changes pre-medication of it after the IR onset with Zolbetuximab 2 course eyes, and continues treatment 花井誠, 鈴木貴之, 中山季昭 Journal of Japanese Society of Pharmaceutical Oncology 41: 203-203, 2025. |
|---|
|
|
O8-04. 1 case that showed a recall phenomenon after the doxorubicin extravasation at the Pola-R-CHP therapy 杉富行1,2), 才郷博久2), 花井誉2) Journal of Japanese Society of Pharmaceutical Oncology 41: 204-204, 2025. |
|---|
|
|
O8-05. It is a case of the cancer of endometrium with suspected recall phenomenon of the radiation enteritis by a Lenvatinib + Pembrolizumab therapy reintroduction after the abdominal radiotherapy 永井大地1), 岡崎秀太1), 越田裕一郎2), 金本巨万2), 鎌田実3), 高橋一栄1) Journal of Japanese Society of Pharmaceutical Oncology 41: 205-205, 2025. |
|---|
|
|
O8-06. About the case that a pharmacist specialized in foreign cancer treatment supported the intervention to the foreign cancer medical treatment patients in other drugstores through medication consultation with the online 木村萌美1), 相原真陽1), 近藤みなみ2), 本田雅志3), 井本圭亮3) Journal of Japanese Society of Pharmaceutical Oncology 41: 206-206, 2025. |
|---|
|
|
O9-01. A case which prevented becoming severe of the hyperkalemia by the ST medical mixture accompanied with the decreased renal function, and was able to prevent pneumocystis pneumonia with temozolomide 米田武司1), 上野隼平1), 山崎由香子2), 上原章兵2), 狭間研至3) Journal of Japanese Society of Pharmaceutical Oncology 41: 207-207, 2025. |
|---|
|
|
O9-02. 1 case that patients with progress ascending colon cancer during the maintenance dialysis enforcement underwent mFOLFOX6+Bev therapy and were able to bring in for conversion surgery 藤田康介1), 竹内丙午2,3,4) Journal of Japanese Society of Pharmaceutical Oncology 41: 208-208, 2025. |
|---|
|
|
O9-03. How PHESGO is used at our hospital and patient satisfaction during administration 下間誉之1), 村中徹人2) Journal of Japanese Society of Pharmaceutical Oncology 41: 209-209, 2025. |
|---|
|
|
O9-04. Attempt of the visit to hospital, health insurance pharmacy program of the pharmacy student with the "Sapporo Higashi-ku cancer medical care pharmacist workshop" member institution 菊池健1,8), 徳留章2,8), 藤村拓也3,8), 太田明秀4,8), 鈴木直哉5,8), 辻裕太6,8), 秋山恵里佳7,8), 谷口亮央5,8) Journal of Japanese Society of Pharmaceutical Oncology 41: 210-210, 2025. |
|---|
|
|
O9-05. About the effect that an anticholinergic agent gives for the febrile neutropenia onset: Analysis by the anticholinergic drug risk scale for Japan 加藤杏奈1,2), 水野智博1,2), 加藤滉基1,2), 溝神文博3), 古関竹直1,2), 山田成樹1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 211-211, 2025. |
|---|
|
|
O9-06. Efforts for the calculation of the cancer medical therapy system full addition in our hospital 川嵜椋太, 宮内秀典, 安島亜矢子, 野口周作, 笠原英城 Journal of Japanese Society of Pharmaceutical Oncology 41: 212-212, 2025. |
|---|
|
|
O9-07. Investigation of the effect on change of prescription and patients accompanied with the tapentadol cessation of production 名和亜利沙1), 小林一男1), 松本禎久2), 佐伯吉規2), 臼井優子2), 山口正和1) Journal of Japanese Society of Pharmaceutical Oncology 41: 213-213, 2025. |
|---|
|
|
O9-08. About a decontamination effect by the hypochlorous acid water solution aerosol to the anticancer medicine pollution of the restroom 熊谷史由1), 濱中直美2), 大友眞菜1), 高松謙1), 森川直人3), 栗原誠4), 袰岩靖子1), 内山弘子1), 外岡久和1) Journal of Japanese Society of Pharmaceutical Oncology 41: 214-214, 2025. |
|---|
|
|
O9-09. Examination of the utilization method of patient reported outcome (ePRO) using the electronic device as patients support, the intelligence tool in the cancer domain 後藤敏也, 鈴木直哉, 廣瀬和昭, 太田敦代 Journal of Japanese Society of Pharmaceutical Oncology 41: 215-215, 2025. |
|---|
|
|
O10-01. About the Nobeoka Regimen Seminar 神薗奈津子, 酒井康介, 日高里奈, 猪俣博樹, 河野和子 Journal of Japanese Society of Pharmaceutical Oncology 41: 216-216, 2025. |
|---|
|
|
O10-02. Usefulness evaluation by the tracing paper chase for exclusive use of the cancer chemotherapy 岩田千奈美, 黒川愛美, 井上加菜子, 近藤博紀, 河崎一久, 古俵孝明 Journal of Japanese Society of Pharmaceutical Oncology 41: 217-217, 2025. |
|---|
|
|
O10-03. About an approach of the cooperation full addition 山田剛1), 大塚英一1), 須藤エミ2), 田村賢一2), 伊藤由華2), 都甲大介2), 高橋千晶2), 加藤博和2), 伊東達也2), 嶋崎みゆき2), 安井良子2), 岸本和義2) Journal of Japanese Society of Pharmaceutical Oncology 41: 218-218, 2025. |
|---|
|
|
O10-04. Efforts to the cancer medical therapy system full addition calculation in the Fukuoka Red Cross hospital 福重昇吾, 川野昭, 田代聡美, 杉慎介, 藤永理恵子 Journal of Japanese Society of Pharmaceutical Oncology 41: 219-219, 2025. |
|---|
|
|
O10-05. Efforts of the cancer medical therapy system full addition calculation in our hospital 今井洋志, 加賀麻友美, 門田佳子 Journal of Japanese Society of Pharmaceutical Oncology 41: 220-220, 2025. |
|---|
|
|
O10-06. Efforts of the pharmacist conference by the cancer chemotherapy charge pharmacist 牧原明秀, 吉田弘樹, 鈴木雅人, 高原悠子, 三屋良太, 近藤舞子, 吉見彩香, 渡邊ちひろ Journal of Japanese Society of Pharmaceutical Oncology 41: 221-221, 2025. |
|---|
|
|
O10-07. Efforts to the cancer medical therapy system full addition acquisition in our hospital 前田哲志, 江尻将之, 安藤究, 近藤優樹, 後藤健志 Journal of Japanese Society of Pharmaceutical Oncology 41: 222-222, 2025. |
|---|
|
|
O10-08. Questionary survey for a physician, hospital pharmacist, the drugstore pharmacists about the foreign cancer medical therapy tracing report 高木麻衣, 渡部大介, 北爪賀子, 宇田川涼子, 浅野智央, 齋藤義正, 橋本浩伸 Journal of Japanese Society of Pharmaceutical Oncology 41: 223-223, 2025. |
|---|
|
|
O10-09. The system maintenance of by pharmacist medical examination front accompanied with the "cancer medical therapy system full addition" new establishment and the result 石嶋麗, 小川千晶, 長尾嘉真, 赤岩愛記, 大栗宝子, 大塚健太郎, 長山佳之, 今村有那, 軍司剛宏 Journal of Japanese Society of Pharmaceutical Oncology 41: 224-224, 2025. |
|---|
|
|
O11-01. Change of the intervention situation and the quantity of duties by the interview before pharmacist medical examination 黒岩勇人, 上田綾佳, 橋本知樹, 眞継賢一 Journal of Japanese Society of Pharmaceutical Oncology 41: 225-225, 2025. |
|---|
|
|
O11-02. 1 case that prescribed it based on the information that we obtained than a follow-up while a drugstore pharmacist participated in a cancer board hosted by a medical institution regularly, and intervened 小峰大典1), 本田雅志2), 木原零2) Journal of Japanese Society of Pharmaceutical Oncology 41: 226-226, 2025. |
|---|
|
|
O11-03. Start relation ... cancer medical therapy system full addition of the pharmacist to foreign cancer chemotherapy; and ... 佐野隆大1), 古川直登1), 藤田真穂1), 佐子綾香1), 鹿島彩絵1), 永井浩章1), 太田あづさ1), 佐倉小百合1), 安堂有希子3), 村蒔基次2), 上田里恵1) Journal of Japanese Society of Pharmaceutical Oncology 41: 227-227, 2025. |
|---|
|
|
O11-04. It is ... for enhancement of efforts of the cooperation full addition calculation in our center and the cancer medicine medicine cooperation of evaluation - area 塩川亜弥乃1), 宮本義浩1), 金子欧作1), 渡辺敦貴1), 野中明日香1), 宮本愛果1), 中島純子1), 池尾優也3), 竹内賢2), 平出耕石1) Journal of Japanese Society of Pharmaceutical Oncology 41: 228-228, 2025. |
|---|
|
|
O11-05. Construction of the prescription support system before medical examination in the pharmacist outpatient department 香内綾1), 木本真司1), 河原史明1), 齋藤浩司1), 成田浩気1), 峯岸智之1), 竹村真生子2), 水谷知央2) Journal of Japanese Society of Pharmaceutical Oncology 41: 229-229, 2025. |
|---|
|
|
O11-06. Effect of the intervention before physician medical examination of the foreign cancer medical therapy in the drugstore pharmacist 舩橋理佳子, 北田優介, 中村和真 Journal of Japanese Society of Pharmaceutical Oncology 41: 230-230, 2025. |
|---|
|
|
O12-01. The current situation of PBPM in the chemotherapy of our hospital 向井光一朗, 東久美子 Journal of Japanese Society of Pharmaceutical Oncology 41: 231-231, 2025. |
|---|
|
|
O12-02. Efforts to the exposure to crush drug measures 鈴木大介 Journal of Japanese Society of Pharmaceutical Oncology 41: 232-232, 2025. |
|---|
|
|
O12-03. Sterilitas and medical expenses reduction effect of the medicinal solution at the DVO enforcement using the anticancer agent preparation robot 後藤佳奈1), 青山聖2,5), 近藤周平3), 朝岡みなみ1,5), 堀田祐志1,5), 井上貴子4), 近藤勝弘5,6), 日比陽子1,5) Journal of Japanese Society of Pharmaceutical Oncology 41: 233-233, 2025. |
|---|
|
|
O12-04. It is the change of the preparation duties accompanied with the change of the feh great (R) combination subcutaneous injection from pertuzumab intravenous feeding, trastuzumab intravenous feeding 中川武史1), 池田真菜1), 高橋喜統1), 井口雅史2), 政氏藤玄1) Journal of Japanese Society of Pharmaceutical Oncology 41: 234-234, 2025. |
|---|
|
|
O12-05. Efforts in the drugstore in a side effect evaluation and the instruction to patient in patients with cancer 磯崎弘恵 Journal of Japanese Society of Pharmaceutical Oncology 41: 235-235, 2025. |
|---|
|
|
O12-06. Measures to a start of therapy delay by the HBs antigen-positive revelation just before the cancer medical therapy start 竹本将士, 大久保奈美, 橋本功 Journal of Japanese Society of Pharmaceutical Oncology 41: 236-236, 2025. |
|---|
|
|
P-001. Examination of the usefulness as the pre-rear marker of inflammation, the nutrition index in patients who received Nivolumab + SOX therapy for progress recurrent gastric cancer 大木雅貴1), 中村朗2), 川島美智子1) Journal of Japanese Society of Pharmaceutical Oncology 41: 237-237, 2025. |
|---|
|
|
P-003. Examination of risk factor analysis of the adverse event expression by the Palbociclib and the effect to give for a survival period: Look at the multi-organization combination rear; a mark observational study 奈良修平1), 辻大樹2), 伊藤夕2), 中村和代3), 山本圭祐4), 中尾將彦1), 石川寛5), 嘉屋道裕3), 中垣繁3), 澤昇平6), 田中怜7), 伊藤邦彦2) Journal of Japanese Society of Pharmaceutical Oncology 41: 238-238, 2025. |
|---|
|
|
P-005. Risk factor analysis about protein urine expression of Cabozantinib in nephrocyte cancer 廣原成, 谷川大夢, 服部友香, 平綿洋子, 丸谷善紀, 鈴木優司 Journal of Japanese Society of Pharmaceutical Oncology 41: 239-239, 2025. |
|---|
|
|
P-007. Investigation about the proper use situation at Tegafur gimeracil oteracil potassium combination drug introduction 花形香歩, 福嶋知樹, 永井友視, 東條汐里, 小林みわ子, 橘田文彦, 鈴木貴明 Journal of Japanese Society of Pharmaceutical Oncology 41: 240-240, 2025. |
|---|
|
|
P-009. The evaluation of the factor about aggravation of anemia with the PARP inhibitor and examination of the usefulness of the Ninjin'yoeito 田初夏苗1), 高田慎也1), 山岸佳代1), 見延進一郎2), 渡邊健一3), 橋下浩紀1) Journal of Japanese Society of Pharmaceutical Oncology 41: 241-241, 2025. |
|---|
|
|
P-011. The effect that the steroid of retching, vomiting measures by the chemotherapy induction gives for an immune-mediated adverse event 筒井佑紀1,3), 藤本愛理2), 高武嘉道3), 中原萌子3), 薮内由里香4), 上田和明4), 松尾圭祐5), 最勝寺雅広6), 上原智博7), 川俣洋生8) Journal of Japanese Society of Pharmaceutical Oncology 41: 242-242, 2025. |
|---|
|
|
P-013. Relationship between Venetoclax blood concentration and efficacy, and drug-drug interactions that affect blood concentration 甲斐絢香1), 萩原政夫2), 杉富行1,3) Journal of Japanese Society of Pharmaceutical Oncology 41: 243-243, 2025. |
|---|
|
|
P-015. Effect of the pain-killer drug candidate on paclitaxel-induced acute pain 佐藤葵1), 相田和輝1), 杉富行2), 野澤 (石井) 玲子1) Journal of Japanese Society of Pharmaceutical Oncology 41: 244-244, 2025. |
|---|
|
|
P-017. The current situation investigation of by physician medical examination front by the pharmacist in the cancer medical therapy 櫻井登代子, 伴具也, 長谷川広樹, 三浦誠 Journal of Japanese Society of Pharmaceutical Oncology 41: 245-245, 2025. |
|---|
|
|
P-019. Examination about the readministration for the oxaliplatin hypersensitivity reaction in patients with gastrointestinal carcinoma 渥美仁, 柴本秀太, 佐竹啓彰, 中山貴美子 Journal of Japanese Society of Pharmaceutical Oncology 41: 246-246, 2025. |
|---|
|
|
P-021. Making of the CRS/ICANS in-hospital initial correspondence flow in the bi-specific antibody molecule medicine administration 田中亜弥1), 衛藤智章1), 崔日承2), 末廣陽子2) Journal of Japanese Society of Pharmaceutical Oncology 41: 247-247, 2025. |
|---|
|
|
P-023. Association with nutrition index by the triple-drug therapy including the paclitaxel of the non-small cell lung cancer and side effect and treatment success period (TTF) 初山多恵1), 松下拓夢2), 橋野泰良3), 後藤桂輔1), 片岡優太1), 荒木有希1), 岩田梨沙1), 松木美緒1), 星貴薫2), 若本あずさ1), 佐藤秀紀1) Journal of Japanese Society of Pharmaceutical Oncology 41: 248-248, 2025. |
|---|
|
|
P-025F. "Clinical significance of the administration start time CRP/ALB ratio (CAR) measurement in the anamorelin application case" 牛膓明広1), 大平直樹1), 吉野真樹2), 嘉藤綾子1), 上田深理1), 樋口智恵1), 佐々木奈穂1), 田川千明1), 田中佳美1), 青柳和代1) Journal of Japanese Society of Pharmaceutical Oncology 41: 249-249, 2025. |
|---|
|
|
P-027F. It is examination about NLR and CAR and the treatment continuation at the beginning of the nal-IRI+5-FU/l-LV therapy 新地瑠海, 浦田修平, 大野梨絵, 南謙太朗, 幸妻貴子, 池田龍二 Journal of Japanese Society of Pharmaceutical Oncology 41: 250-250, 2025. |
|---|
|
|
P-029F. Comparison of an administration timing and the renal failure protective efficacy of furosemide for the cisplatin-induced renal failure 脇岡葵1), 林稔展1), 三好孝法2), 川満啓司1), 牛尾聡一郎1), 江川孝1) Journal of Japanese Society of Pharmaceutical Oncology 41: 251-251, 2025. |
|---|
|
|
P-173F. One case that the follow-up by the drugstore pharmacist contributed to the early correspondence of the cytokine-releasing syndrome 糸井陽介1), 宍戸桃子2), 井上靖隆2), 伊藤将3), 長谷川佳孝3), 月岡良太3), 大石美也3), 後藤仁和2) Journal of Japanese Society of Pharmaceutical Oncology 41: 252-252, 2025. |
|---|
|
|
P-215. Onset of diarrhea risk analysis with the immune checkpoint inhibitor using adverse drug reaction database (JADER) 五十嵐爽1), 前田守2), 伊藤将2), 長谷川佳孝2), 月岡良太2), 大石美也2) Journal of Japanese Society of Pharmaceutical Oncology 41: 253-253, 2025. |
|---|
|
|
P-217. Review of the administration standard table in the gynecologic regimen 吉田美和, 宍倉啓介, 大村由紀子 Journal of Japanese Society of Pharmaceutical Oncology 41: 254-254, 2025. |
|---|
|
|
P-219. Pharmacist intervention (FORECAST study) in the follow-up utilizing ePRO for oral anticancer medicine-treated patients 滝澤健司1), 大野春菜1), 藤崎玲子1), 大瀧翔2), 三ツ木梨絵2), 岡田寛征2), 添石遼平2), 藤宮龍祥3), 川口崇3), 山口拓洋4) Journal of Japanese Society of Pharmaceutical Oncology 41: 255-255, 2025. |
|---|
|
|
P-221. Examination about the association between use of breast cancer preparation and employment situation, productivity loss by the real world data utilization 滝沢治1), 山田雄矢2), 五十嵐中1) Journal of Japanese Society of Pharmaceutical Oncology 41: 256-256, 2025. |
|---|
|
|
P-223F. The construction of the predictive model of the dietary AUC increase for the oral antitumor agents and adaptation to supportive care medicine, and the like 宮島利奈, 中島俊太, 上野秀, 杉山里奈, 中山文華, 前島多絵, 渡邊真知子, 板垣文雄 Journal of Japanese Society of Pharmaceutical Oncology 41: 257-257, 2025. |
|---|
|
|
P-031. The current situation investigation about the side effect expression in cancer chemotherapy patients using oxaliplatin and the capecitabine 岸本真1,2), 徳丸章佳1), 徳永楓果1), 上野菜巳1), 前田裕太1), 六田晃士1), 北園幸大1), 屋敷大輔1), 長ヶ原琢磨1), 荻尾夕起子1), 徳永仁2) Journal of Japanese Society of Pharmaceutical Oncology 41: 258-258, 2025. |
|---|
|
|
P-033. CRS occurrence after Epcolitamab administration at our hospital 阿部結哉1), 西原夢乃1), 野口唯香1), 木村雄太1), 高田慎也1), 山岸佳代1), 高橋承吾2), 江端浩2), 坂井俊哉2), 藤本勝也2), 橋下浩紀1) Journal of Japanese Society of Pharmaceutical Oncology 41: 259-259, 2025. |
|---|
|
|
P-035. Survey of the current status of Erlanatamab therapy and adverse events for relapsed or refractory multiple myeloma at our hospital 栗原りか, 小池美紀, 村松茂代, 濱中悠賀, 新行内健一, 横尾祐一, 金井貴充 Journal of Japanese Society of Pharmaceutical Oncology 41: 260-260, 2025. |
|---|
|
|
P-037. The use situation investigation of the immune checkpoint inhibitor screening test set 今川貴仁, 小池慶彦, 上岡彩佳, 大澤勇貴, 千葉達夫, 木村麗砂, 小林加寿子, 日浦寿美子, 小林秀樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 261-261, 2025. |
|---|
|
|
P-039. About an investigation of the use of Zolbetuximab situation in our hospital and the side effect expression situation 鈴木雅人, 吉田弘樹, 渡邊ちひろ, 吉見彩香, 近藤舞子, 三屋良太, 牧原明秀, 安田知弘, 高原悠子, 木全司 Journal of Japanese Society of Pharmaceutical Oncology 41: 262-262, 2025. |
|---|
|
|
P-041. The process of introducing Trastuzumab deruxtecan in a facility without a pulmonologist 虻川詩希子1), 浪岡恭子2), 奥村文彦3) Journal of Japanese Society of Pharmaceutical Oncology 41: 263-263, 2025. |
|---|
|
|
P-043F. Characteristic of the patients whom progression-free survival period extends to by the treatment by adverse event interruption of the KEYNOTE189 regimen 川本日和李1), 森翔馬2,3), 毎熊隆誉1,2), 吉井圭佑1), 森谷康志4), 高田遼5), 新開史崇6), 春木祐人3), 橋本ひかり1), 広本篤1), 高柳和伸4), 田村浩二5), 大倉裕祐6), 杉山哲大3), 島田憲一1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 264-264, 2025. |
|---|
|
|
P-045. Effect on taste disturbance when we added the molecular target medicine to capecitabine + oxaliplatin therapy and oral mucositis 山田将悟, 藤林遼, 田中耕太, 朝倉幹己, 高橋誠, 前川英輝, 山本翔太, 菊地亮郎, 橋本咲季, 山内萌生, 齋藤公華, 田中正臣 Journal of Japanese Society of Pharmaceutical Oncology 41: 265-265, 2025. |
|---|
|
|
P-047F. Examination of the tolerability in the rituximab 90 minutes drip method: Rearward observational study with the single institution 谷畑美里, 槙原克也, 基村佳世, 金剛圭佑, 福井梨乃, 木本大樹, 沖礼子, 松村友和 Journal of Japanese Society of Pharmaceutical Oncology 41: 266-266, 2025. |
|---|
|
|
P-049. The effect that the proton pump inhibitor combination in the nivolumab + chemotherapy combination patients gives for renal function 三柳心路, 谷垣雄都, 松岡智美, 安達嘉織, 前原大輔, 藤原康浩, 本間久美子 Journal of Japanese Society of Pharmaceutical Oncology 41: 267-267, 2025. |
|---|
|
|
P-051. The efforts course of the pharmacist in the foreign chemotherapy center and pharmaceutical intervention analysis 村上幸恵, 樋口理恵, 山岸良寛, 桑原玄樹, 桑原里菜, 山本剛 Journal of Japanese Society of Pharmaceutical Oncology 41: 268-268, 2025. |
|---|
|
|
P-053F. Use experience of feh great (R) in our hospital 杉山みなみ, 川崎佳名子, 渡邉愛悠, 佐藤正太郎, 中井麻木 Journal of Japanese Society of Pharmaceutical Oncology 41: 269-269, 2025. |
|---|
|
|
P-055. The system construction for the cancer medical therapy system full addition acquisition in the middle scale hospital and the effect 鯉淵寛之1), 廣瀬直樹1), 山村朝子2), 片岡美千代2), 貴島孝3), 谷川浩司1) Journal of Japanese Society of Pharmaceutical Oncology 41: 270-270, 2025. |
|---|
|
|
P-057F. Search about the change of the clinical test value at the irAE onset 倉井岳史, 村上賢志, 佐藤学 Journal of Japanese Society of Pharmaceutical Oncology 41: 271-271, 2025. |
|---|
|
|
P-059. Investigation about the correspondence at the extravasation with the cancer medical therapy 宮澤憲治1,19), 桂英之2,19), 有原大貴3,19), 安藤友貴4,19), 大屋正宏5,19), 熊谷要6,19), 猿谷淳7,19), 高倉美穂8,19), 瀧本真紀9,19), 田村健吾10,19), 茶野下貴恵11,19), 戸塚弘幸12,19), 西上真13,19), 堀祐貴14,19), 宮永和美15,19), 吉田宗広16,19), 林誠17,19), 新谷圭子18,19), 笹山潔16,19) Journal of Japanese Society of Pharmaceutical Oncology 41: 272-272, 2025. |
|---|
|
|
P-061F. The search of the predictor of the acute phase treatment by serious adverse effect of the oral anticancer medicine: Single institution study (2,020-2,021 years) 寺本美咲1), 川澄賢司2), 古岡桃果2), 川崎敏克2), 佐藤嗣道3), 永田将司4), 河野洋平1) Journal of Japanese Society of Pharmaceutical Oncology 41: 273-273, 2025. |
|---|
|
|
P-063. Evaluation of by medical examination front in the foreign cancer chemotherapy 石川夏波, 中島優子, 黒川俊光, 野澤彰 Journal of Japanese Society of Pharmaceutical Oncology 41: 274-274, 2025. |
|---|
|
|
P-065. The role that a drugstore pharmacist should fulfil in the foreign cancer chemotherapy using the molecular target medicine 一戸秀太1), 吉川美穂2), 工藤可奈子3), 伊藤将4), 長谷川佳孝4), 月岡良太4), 大石美也4) Journal of Japanese Society of Pharmaceutical Oncology 41: 275-275, 2025. |
|---|
|
|
P-067. About the operation of the regimen including the Zolbetuximab 村上達哉, 江原美里, 松本健吾, 竹松茂樹, 松井尚美, 永井聡子 Journal of Japanese Society of Pharmaceutical Oncology 41: 276-276, 2025. |
|---|
|
|
P-069F. Inspection of the risk factor of Infusion-Related Reaction by the trastuzumab 松井優奈, 堀智貴, 尾崎智規, 吉岡奈津恵, 生島繁樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 277-277, 2025. |
|---|
|
|
P-071. About the use situation of the pertuzumab trastuzumab combination subcutaneous injection preparation in our hospital 木下智広, 坂本亜佐子, 横田智也, 岩田和弥 Journal of Japanese Society of Pharmaceutical Oncology 41: 278-278, 2025. |
|---|
|
|
P-073. Efforts of by front part of medical examination of the team system for all patients of the administration second in the injection cancer chemotherapy (pharmacist outpatient department) and the evaluation 坂本靖宜, 宇山佳奈, 清水絢子, 重村明香, 長谷川拓也, 長井絵里奈, 小泉宏史, 山本幸二郎, 内田寿恵, 太田一郎, 小森智也, 井出和男, 若杉正, 小池博文, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 41: 279-279, 2025. |
|---|
|
|
P-075. Rearward search study on predictor of the side effect of the docetaxel + ramucirumab therapy for patients with non-small cell lung cancer 中村俊之1), 野田哲史2), 大岡千寿子1), 田久保康隆3), 野口哲男4), 野冽孝二1) Journal of Japanese Society of Pharmaceutical Oncology 41: 280-280, 2025. |
|---|
|
|
P-077. Comparison of neutropenia, FN frequencies of Doublet + BV therapy and the FOLFOXIRI + BV therapy in colon cancer 野口ひなた1), 村山三佳2), 中村智絵3), 細見周平3), 溝口博之3), 阿部多一1), 井口恵美子1), 山田清文4) Journal of Japanese Society of Pharmaceutical Oncology 41: 281-281, 2025. |
|---|
|
|
P-079F. The current situation investigation of the in front of cancer treatment-related cardiovascular toxic treatment with anthracycline anticancer medicine risk 渡邉倫, 坂本靖宜, 西垣哲太, 清水絢子, 小泉宏史, 宇山佳奈, 長谷川拓也, 重村明香, 小池博文, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 41: 282-282, 2025. |
|---|
|
|
P-081. Examination of the cancellation standard factor of the unresectable pancreatic cancer chemotherapy 宮部貴識, 関口知弘, 多田純平, 及川悠衣, 澤田奈々, 東谷素直, 山口志郎, 中島淳, 原伸好 Journal of Japanese Society of Pharmaceutical Oncology 41: 283-283, 2025. |
|---|
|
|
P-083. Examination of the effectiveness of the steroid drug for external use application period for the mouse extravasation model with vincristine 牧島里紗1), 平山純鈴1), 野澤 (石井) 玲子2), 杉富行1) Journal of Japanese Society of Pharmaceutical Oncology 41: 284-284, 2025. |
|---|
|
|
P-085. Investigation of the dysfunction thyroid with the immune checkpoint inhibitor and the management situation 辻井大輔, 松本陽子 Journal of Japanese Society of Pharmaceutical Oncology 41: 285-285, 2025. |
|---|
|
|
P-087. Examination about the intervention of usefulness and the pharmacist of GLS in the use of trastuzumab patients 大田晴香, 坂田采弥香, 波部未央佳, 谷畑文彩, 初田愛子, 沼田範子, 日生下美紀, 柴田直子 Journal of Japanese Society of Pharmaceutical Oncology 41: 286-286, 2025. |
|---|
|
|
P-089. Inspection ... of the effect on retching, vomiting when we changed examination - 5-HT3 receptor blocker of the supportive care change of the registration regimen to second generation 岡崎直樹, 前畠一友, 六田湧紀, 高橋真理 Journal of Japanese Society of Pharmaceutical Oncology 41: 287-287, 2025. |
|---|
|
|
P-091F. Look at the rear about the factor of the excretion delay in the methotrexate massive dose therapy; mark investigation 草加嵩士1,3), 遠藤晋吾1), 鶴島克将1), 小川直希1), 藤井千賀1), 藤井一美1), 安井友佳子2), 石坂敏彦2), 小竹武3) Journal of Japanese Society of Pharmaceutical Oncology 41: 288-288, 2025. |
|---|
|
|
P-093. Use fact-finding of the Gee raster (R) body pod in the Osaka University faculty of medicine hospital 廣重佑香, 小林暉英, 池村健治, 渡邊梓, 山本智也, 奥田真弘 Journal of Japanese Society of Pharmaceutical Oncology 41: 289-289, 2025. |
|---|
|
|
P-095F. One case that control of retching vomiting suffered from by cancer chemotherapy and the onset of the superior mesenteric artery syndrome 柄沢良惠1), 堀越慶一1), 濱田浄司2) Journal of Japanese Society of Pharmaceutical Oncology 41: 290-290, 2025. |
|---|
|
|
P-097. A case of pregnancy-related breast cancer treated with dose-dense AC (ddAC) → weekly PTX (wPTX) therapy 遠藤美央, 畠山智明, 玉木慎也 Journal of Japanese Society of Pharmaceutical Oncology 41: 291-291, 2025. |
|---|
|
|
P-099. One case that a cytokine-releasing syndrome recurred after the checkpoint inhibitor cancellation of immunity 吉田勝好1), 河野将大1), 大谷崇仁1), 田原明子1), 服部晋司2), 郷原学1) Journal of Japanese Society of Pharmaceutical Oncology 41: 292-292, 2025. |
|---|
|
|
P-101. One case report that dexrazoxane raised extravasation during diffuse large-cell B-cell lymphoma treatment 若宮奈央1), 鈴木正論2), 伊勢崎竜也3), 舟越亮寛3) Journal of Japanese Society of Pharmaceutical Oncology 41: 293-293, 2025. |
|---|
|
|
P-103F. It is a case receiving the linagliptin for a response to diabetes with the anamorelin administration 仲尾洋子1), 大森克哉3), 土井千亜紀1), 高木慎司1), 園生渚1), 三浦尚子1), 阿相徹2), 宮田広樹4), 福土将秀3) Journal of Japanese Society of Pharmaceutical Oncology 41: 294-294, 2025. |
|---|
|
|
P-105. Construction and onset of adverse event advisory of the simpler and easier medication method of the Zolbetuximab in our area 洞口拓也, 井上昇, 大澤琢郎, 嶋俊弥, 山本和哉, 長瀬翔太, 牧野紗季, 日江井花菜, 上田秀親, 若田達朗 Journal of Japanese Society of Pharmaceutical Oncology 41: 295-295, 2025. |
|---|
|
|
P-107F. A case of cytokine storm (CRS) after durvalumab plus tremelimb (DUR + TRM) administration in a lung cancer patient 保井健太, 森本健幹, 森下拓哉, 福田利明 Journal of Japanese Society of Pharmaceutical Oncology 41: 296-296, 2025. |
|---|
|
|
P-109. Monitoring blood niraparib concentrations in patients with ovarian cancer 丸藤義翔1,2), 岩瀬春子3), 城田幹生1,4), 安武夫1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 297-297, 2025. |
|---|
|
|
P-111. A case which introduced steroid for irAE enterocolitis with the Durvalumab + Tremelimumab combination therapy, and produced interstitial lung disease during gradual decrease newly 松本健吾, 江原美里, 明石直子, 竹松茂樹, 松井尚美, 永井聡子 Journal of Japanese Society of Pharmaceutical Oncology 41: 298-298, 2025. |
|---|
|
|
P-113. A case which produced irAE gastritis during nivolumab therapy 小嶋恭平1), 滝花義男2), 三科友二3) Journal of Japanese Society of Pharmaceutical Oncology 41: 299-299, 2025. |
|---|
|
|
P-115. Three cases of macrocytic anemia that developed during the CAPOX therapy enforcement 増野貴司, 黒澤瑛里, 上田由紀, 櫻井望, 岩崎英久, 堀口裕之 Journal of Japanese Society of Pharmaceutical Oncology 41: 300-300, 2025. |
|---|
|
|
P-117F. Effect of treatment of the steroid medicine for external application for the acneform rash after the cetuximab resumption 足立璃里子1), 沢仁1,4), 平安奈美子2), 岸下陽子2), 小西健3), 中村暢彦5) Journal of Japanese Society of Pharmaceutical Oncology 41: 301-301, 2025. |
|---|
|
|
P-119. A case in which a pharmacist's relationship of trust with a patient taking ixazomib citrate led to early detection and treatment of severe diarrhea 高柳ふみ枝1), 善明慎平1), 高野七緒1), 前田守2), 長谷川佳孝2), 月岡良太2), 大石美也2) Journal of Japanese Society of Pharmaceutical Oncology 41: 302-302, 2025. |
|---|
|
|
P-121. One case of the EDP-M therapy for patients with adrenal cortex cancer with the slight decreased renal function 大平サラ1), 渡邉俊2), 木村純子1), 白石童子1), 酒井敏直1), 早乙女彩子3), 早乙女浩之1) Journal of Japanese Society of Pharmaceutical Oncology 41: 303-303, 2025. |
|---|
|
|
P-123. Pharmaceutical intervention case for the adverse event of the Zolbetuximab + CAPOX therapy 島袋優花, 川上博瀬, 前泊美保, 知念里佳, 松島亜紀, 糸満盛尚, 本村恵, 大城優衣, 内間千裕, 浜元善仁 Journal of Japanese Society of Pharmaceutical Oncology 41: 304-304, 2025. |
|---|
|
|
P-125. 1 case of patients with lung cancer that developed congestive heart failure after the Osimertinib start 尾形美絵, 近藤和宏, 羽生智宏, 新関みどり, 長澤欣弘, 中村槙一郎, 鈴木美結, 田村和彦 Journal of Japanese Society of Pharmaceutical Oncology 41: 305-305, 2025. |
|---|
|
|
P-127. Fact-finding of the steroid spare ring by the mFOLFOX6, FOLFIRI therapy 鹿間友絵, 高木淳也, 海野祥生, 張友樹, 細田菜摘, 木原星衣, 前田美紀, 生田和之, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 41: 306-306, 2025. |
|---|
|
|
P-129F. The adverse event onset of Zolbetuximab administration 3 case situation in our hospital 岩崎愛弓, 青井博志, 治田匡平, 谷田彩, 小川恵美子, 池田和之 Journal of Japanese Society of Pharmaceutical Oncology 41: 307-307, 2025. |
|---|
|
|
P-131F. Inspection of the effectiveness of the fosnetupitant in the CAPOX therapy 武島宙, 山本紗織, 平良智, 森脇典子 Journal of Japanese Society of Pharmaceutical Oncology 41: 308-308, 2025. |
|---|
|
|
P-133. The case that a pharmacist was able to discover SIADH during checkpoint inhibitor and treatment of immunity with platinum doublet early 神田沙季1), 辻本朗1), 宗哲哉2) Journal of Japanese Society of Pharmaceutical Oncology 41: 309-309, 2025. |
|---|
|
|
P-135. It is a case receiving CCRT of mitomycin C and the capecitabine for anal canal basaloid carcinoma 中島優子1), 黒川俊光1), 石川夏波1), 知久毅2), 野澤彰1) Journal of Japanese Society of Pharmaceutical Oncology 41: 310-310, 2025. |
|---|
|
|
P-137. It is one patient using olanzapine for inappetence, nausea found during concurrent chemoradiotherapy duration of treatment 張光雄大1), 林稔展1), 秋吉正貴2), 後藤美緒2), 江川孝1), 渡邊裕之2) Journal of Japanese Society of Pharmaceutical Oncology 41: 311-311, 2025. |
|---|
|
|
P-139. 1 case that the conversion ratios from a hydromorphone continuous intravenous infusion to an oral formulation were not constant 栗原啓輔1), 山田洋介2), 荒川大輔1), 清水真弓1), 辻村行啓1), 村上はる香1), 米山萌1), 矢部勝茂1) Journal of Japanese Society of Pharmaceutical Oncology 41: 312-312, 2025. |
|---|
|
|
P-141. A case of RET fusion gene-positive recurrent thyroid cancer treated with selpercatinib after gastrectomy 殿村直也1), 土居千聖1), 丸藤義翔2), 安武夫2), 山口智1) Journal of Japanese Society of Pharmaceutical Oncology 41: 313-313, 2025. |
|---|
|
|
P-143. Use experience and consideration in our hospital of combination subcutaneous injection preparation feh great (R) 萩原知佳1), 柿本秀樹1), 福江悠香1), 吹上勇真1), 上田裕1), 江口実里1), 中島章雄1,2), 宮崎元康1,2), 今給黎修1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 314-314, 2025. |
|---|
|
|
P-145. A case of the anticancer agent administration to patients with cancer of the aspirin asthma suspicion 太田恵, 丸山真一, 菅野浩 Journal of Japanese Society of Pharmaceutical Oncology 41: 315-315, 2025. |
|---|
|
|
P-147. Use report of the Zolbetuximab in the Yokohama Sakae mutual aid hospital 中山裕貴, 山田裕之, 田隝博樹, 松浦志保 Journal of Japanese Society of Pharmaceutical Oncology 41: 316-316, 2025. |
|---|
|
|
P-149. One case of the foreign chemotherapy support utilizing eDIARY 金澤亜梨沙, 都築竜太, 香取哲哉, 小茂田昌代, 出雲貴文 Journal of Japanese Society of Pharmaceutical Oncology 41: 317-317, 2025. |
|---|
|
|
P-151F. A case which hypoglycemia, a low Na blood symptom, eosinophilia were mild, but developed adrenal insufficiency during nivolumab administration 高田幸裕, 輿石徹, 吉元公一 Journal of Japanese Society of Pharmaceutical Oncology 41: 318-318, 2025. |
|---|
|
|
P-153. Use experience of the zoledronic acid to patients with solid carcinoma metastases to bone with the severe impaired renal function 三上貴弘, 内田敬, 林克剛, 猪岡京子 Journal of Japanese Society of Pharmaceutical Oncology 41: 319-319, 2025. |
|---|
|
|
P-155F. It is a 1 case with suspected cognitive functional decline by mogamulizumab administration for patients with CCR4-positive adult T-cell leukemia/lymphoma 小田実季1), 小川千晶1), 大塚健太郎1), 赤岩愛記1), 大栗宝子1), 長山佳之1), 石嶋麗1), 今村有那1), 長尾嘉真1), 籠尾壽哉2), 清水隆之2), 軍司剛宏1) Journal of Japanese Society of Pharmaceutical Oncology 41: 320-320, 2025. |
|---|
|
|
P-157F. A case of drug-related osteonecrosis of the jaw caused by epcoritamab treatment in a patient receiving denosumab 箕輪僚耶1), 花房喜子1), 山中光1), 吉川慧2), 草野元1) Journal of Japanese Society of Pharmaceutical Oncology 41: 321-321, 2025. |
|---|
|
|
P-159. Intervention for patients with lung cancer that started an ABCP (ATZ + BEV + CBDCA + PTX) therapy as the second treatment 澤井一1), 赤嶺美奈1,2), 赤嶺有希子2), 加納美知子1,2), 久野木良子1), 高木正信1,2), 田中祥子1,2), 堀泰羽1,2), 松尾律子1,2), 姜惠元1), 平野陽子2), 谷田弘3) Journal of Japanese Society of Pharmaceutical Oncology 41: 322-322, 2025. |
|---|
|
|
P-161F. A case which developed irAE enteritis in the patients with cholangiocarcinoma with the cancerous peritonitis 井上大輝1), 長井洋樹2), 野本弘章2), 宮下淳1), 畑山愛1) Journal of Japanese Society of Pharmaceutical Oncology 41: 323-323, 2025. |
|---|
|
|
P-163. The case that a drugstore pharmacist intervened in for patients with colon cancer with comorbidities 赤嶺美奈1,2), 縄田裕子4), 赤嶺有希子1), 加納美知子1,2), 久野木良子2), 高木正信1,2), 田中祥子1,2), 堀泰羽1,2), 松尾律子1,2), 姜惠元2), 平野陽子1), 谷田弘3), 澤井一2) Journal of Japanese Society of Pharmaceutical Oncology 41: 324-324, 2025. |
|---|
|
|
P-165F. One case that caused hypopituitarism by steroid-containing drug combination during Ipi+Nivo combination therapy, and treated it, and delayed 青野花音1), 沢仁美1,4), 前田幸千恵1), 河野友彰2), 宇野彩3), 中村暢彦5) Journal of Japanese Society of Pharmaceutical Oncology 41: 325-325, 2025. |
|---|
|
|
P-167. A case in which skin disorders and hand-foot syndrome caused by the BEACON regimen made it difficult to break away from PTP with encorafenib 輿石徹, 高田幸裕, 山本佳苗, 吉元公一 Journal of Japanese Society of Pharmaceutical Oncology 41: 326-326, 2025. |
|---|
|
|
P-169. A case which developed treatment-related leukemia during PARP inhibitor maintenance therapy for ovarian cancer 原田悠介1), 四十物由香1), 小川竜徳1), 小川愛梨1), 渡邉久美子2), 海江田拓実3), 田村明広1) Journal of Japanese Society of Pharmaceutical Oncology 41: 327-327, 2025. |
|---|
|
|
P-171. 1 case of patients with pancreatic cancer connected by early detection of the obstructive jaundice in direct hospital admission of emergency by telephone support 岩本翔1), 松下明奈1), 溝上泰仁2,3) Journal of Japanese Society of Pharmaceutical Oncology 41: 328-328, 2025. |
|---|
|
|
P-175. It is efforts ... as the cottage-hospital out of ... about the cooperation full addition of our hospital 山田憲和 Journal of Japanese Society of Pharmaceutical Oncology 41: 329-329, 2025. |
|---|
|
|
P-177. Usefulness of efforts and by medical examination front of our hospital in the cancer medical therapy system full addition 臼井崇1), 横山正人1), 山中義裕1), 朝日恵美2), 山田紘平3) Journal of Japanese Society of Pharmaceutical Oncology 41: 330-330, 2025. |
|---|
|
|
P-179. Efforts for the workshop holding as the specialty medical institution cooperation drugstore in consideration of continuity 山崎友里絵1), 比嘉耕基1), 鈴木直哉2), 木下隆市2), 谷口亮央2), 中島史雄2) Journal of Japanese Society of Pharmaceutical Oncology 41: 331-331, 2025. |
|---|
|
|
P-181. Examination of the usefulness of the tracing report electronic introduction in the cancer medical therapy 柳野紗智子1), 有田仁紀1), 花井雄貴2), 渡辺和美1), 宮田祥一1), 難部仁美1), 坂本真紀1), 松本高広1) Journal of Japanese Society of Pharmaceutical Oncology 41: 332-332, 2025. |
|---|
|
|
P-183. Future prospects ... which the grasp of fact-finding - current situation of the cooperation full addition in our hospital and the opinion of the outside Parliament drugstore were based on 青木洸英1), 小谷野大地1), 佐々木茂樹1), 金井詩織1), 細渕明日美1), 岸稔2), 杉田和夫1) Journal of Japanese Society of Pharmaceutical Oncology 41: 333-333, 2025. |
|---|
|
|
P-185. We were able to see it from the questionnaire after ... study session about cooperation with a pharmacist and the dietitian in the nourishment diet advice of patients with cancer 目黒聡子1), 高橋千遥2), 小田慎1) Journal of Japanese Society of Pharmaceutical Oncology 41: 334-334, 2025. |
|---|
|
|
P-187. About calculation and efforts of the cancer medical therapy system full addition in the Hakujuji Hospital 水之江峻介, 田川慎二, 中村郁勝, 矢野瑞紀, 高津宏典 Journal of Japanese Society of Pharmaceutical Oncology 41: 335-335, 2025. |
|---|
|
|
P-189. Efforts of the cancer medical therapy system full addition in the Himeji medical center 江原美里, 松本健吾, 砂田萌, 竹松茂樹, 松井尚美, 永井聡子 Journal of Japanese Society of Pharmaceutical Oncology 41: 336-336, 2025. |
|---|
|
|
P-191. Inventory survey about the workshop to the neighborhood drugstore with the specialized medical institution cooperation drugstore 木ノ下理惠1), 吉田昌登2), 平井慧3), 角佳亮4) Journal of Japanese Society of Pharmaceutical Oncology 41: 337-337, 2025. |
|---|
|
|
P-193. The pharmaceutical management by the interview before medical examination and evaluation of the acceptance rate 平野美絵1), 杉浦龍也1), 城田佳尚1), 服部真奈1), 谷口靖樹1), 小森徹也2) Journal of Japanese Society of Pharmaceutical Oncology 41: 338-338, 2025. |
|---|
|
|
P-195F. Usefulness of the telephone follow-up about the side effect early detection of the breast cancer preoperative chemotherapy 井澤佐知子1), 安藤陽子1), 前川佳子1), 谷口翼1), 佐藤里帆1), 梶原理英子1), 近藤範子1), 舩塚恵子1), 神一樹1), 宮田広樹2) Journal of Japanese Society of Pharmaceutical Oncology 41: 339-339, 2025. |
|---|
|
|
P-197. The enforcement situation of the drug interview before relation and medical examination of the pharmacist in the foreign chemotherapy in our hospital 白藤裕美1), 濱里真耶1), 田和昌以子1), 大平明香1), 松本ミユキ2) Journal of Japanese Society of Pharmaceutical Oncology 41: 340-340, 2025. |
|---|
|
|
P-199. Reinforcement of the anticancer agent medicine medicine cooperation by the tracing report utilization 白石貴之 Journal of Japanese Society of Pharmaceutical Oncology 41: 341-341, 2025. |
|---|
|
|
P-201. The side effect expression of Abemaciclib situation reported through a tracing report 篠崎千尋1), 柿原圭佑1), 三上忠司1), 野田聖奈子1), 梅崎りさ2), 小笠原珠美3), 浦瀬剛嗣1) Journal of Japanese Society of Pharmaceutical Oncology 41: 342-342, 2025. |
|---|
|
|
P-203. It is ... about a role of content analysis - hospital pharmacist of the foreign cancer medical therapy tracing report and a future problem 小久保祐希, 小川充恵, 井上咲紀, 植田真理, 佐藤浩二, 西岡達也 Journal of Japanese Society of Pharmaceutical Oncology 41: 343-343, 2025. |
|---|
|
|
P-205. About an effect to the cooperation full addition by the multi-type of job conference participation 古川直登, 本上ほなみ, 鹿島彩絵, 佐野隆大, 太田あずさ, 佐倉小百合, 上田里恵 Journal of Japanese Society of Pharmaceutical Oncology 41: 344-344, 2025. |
|---|
|
|
P-207. Efforts for the construction of the follow-up system after the anthracycline anticancer medicine administration and regional alliances 坂居知憲1,2), 蔵田靖子1), 岩田直大1), 村尾卓哉1), 武田達明3), 福武恵4), 渡邊亜津子4), 田端雅弘4), 田中雄太1), 濱野裕章1,2), 座間味義人1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 345-345, 2025. |
|---|
|
|
P-209. Attempt ... of the workshop holding for the purpose of the construction of current situation and problem ... medicine medicine cooperation that looked at the rear of the chemotherapy reporting book, and were obtained by mark investigation which is easy to collaborate 山本千尋1), 中村美智子1), 山崎裕己2), 西垣賢3), 井口仁美4), 志野訓之4) Journal of Japanese Society of Pharmaceutical Oncology 41: 346-346, 2025. |
|---|
|
|
P-211. Establishment and the intervention actual situation of the cancer medical therapy pharmacist outpatient department in our hospital 渡邊雅明, 原田真由美, 市川卓哉, 諏訪淳一, 益子里美 Journal of Japanese Society of Pharmaceutical Oncology 41: 347-347, 2025. |
|---|
|
|
P-213. Examination about the effect on bleeding risk by L-asparaginase and the anticoagulant combination using the adverse event spontaneous report database 奥村俊一, 廣井順子 Journal of Japanese Society of Pharmaceutical Oncology 41: 348-348, 2025. |
|---|
|
|
P-225. About the training enforcement for consciousness reform for the occupational exposure of the drugstore pharmacist 足立昇平1), 大坪亮太郎2), 下川友香理3), 本田雅志3) Journal of Japanese Society of Pharmaceutical Oncology 41: 349-349, 2025. |
|---|
|
|
P-227F. Change of intervention contents before and after the regimen check sheet introduction, examination of the attitude survey 白鳥瞳, 植木大介, 永見恵里奈, 阿部紗彩, 船崎秀樹, 近藤直樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 350-350, 2025. |
|---|
|
|
P-229. Efforts for the standardization of the inspection procedure in the foreign prescription of the internal use anticancer agent 北村真奈美, 三好康介, 景山花奈, 小田怜史, 渡部英明, 梅田勇一 Journal of Japanese Society of Pharmaceutical Oncology 41: 351-351, 2025. |
|---|
|
|
P-231. Efforts to Promote the Proper Use of Aminolevulinic Acid Hydrochloride Granules (ALAGLIO(R)) and the Current Status of Use 岸本幸次, 佐藤浩二, 植田真理, 井上咲紀, 西岡達也 Journal of Japanese Society of Pharmaceutical Oncology 41: 352-352, 2025. |
|---|
|
|
P-233. Anticancer medicine exposure investigation before and after the closed system anesthesia drug transportation system introduction 熊澤崇1), 中村武司1), 尾茂宏美1), 岸本千絵1), 田畑貴康1), 山下秀之1), 原田奈津子2), 山口伸二1) Journal of Japanese Society of Pharmaceutical Oncology 41: 353-353, 2025. |
|---|
|
|
P-235. The anticancer agent exposure situation and problems (the third report) after the closed system anesthesia drug transportation system introduction 坂口貴大, 藤井克知, 加藤剛志, 岩松真理香, 斎藤和悦 Journal of Japanese Society of Pharmaceutical Oncology 41: 354-354, 2025. |
|---|
|
|
P-237F. Efforts aiming at the standardization of the regimen check in the cancer medical therapy 田中健太, 西場弘美, 小材直人, 千吉良幸子, 新木美枝, 蟻川勝 Journal of Japanese Society of Pharmaceutical Oncology 41: 355-355, 2025. |
|---|
|
|
P-239. About introduction and the inflection of the anticancer medicine mixture preparation robot 山口淳美, 本上ほなみ, 前田和輝, 藤田真穂, 永井浩章, 佐野隆大, 太田あづさ, 佐倉小百合, 上田里恵 Journal of Japanese Society of Pharmaceutical Oncology 41: 356-356, 2025. |
|---|
|
|
P-241F. Analysis of the associated factor for the optimization of use of single vial multiple times (DVO) of the anticancer agent 藤田崚介, 森光輝, 守屋昭宏, 浅野裕紀, 木村美智男, 宇佐美英績 Journal of Japanese Society of Pharmaceutical Oncology 41: 357-357, 2025. |
|---|
|
|
P-243F. Investigation of the exposure to anticancer medicine reduction by the introduction of the hypochlorous acid water 小川侑乃, 宍倉啓介, 大村由紀子 Journal of Japanese Society of Pharmaceutical Oncology 41: 358-358, 2025. |
|---|
|
|
P-245F. Efforts of our hospital for the medical expenses inhibition of the antitumor agents 吉成徹, 渡邊紘子, 鈴木健吾, 秋元美咲, 坂本鉄弥 Journal of Japanese Society of Pharmaceutical Oncology 41: 359-359, 2025. |
|---|
|
|
P-247F. Efforts of by medical examination front ... "cancer medical therapy system full addition" by the pharmacist utilizing the foreign chemotherapy room and feedback contents ... to a physician 富山正也, 野村洋道, 住吉佑介, 福嶋浩一, 中浴伸二, 平畠正樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 360-360, 2025. |
|---|
|
|
P-249. About the satisfaction investigation of the injection drug coinfusion inspection system in the anticancer agent preparation 黒部健太郎, 水田秀貴, 塩川裕美, 宮原強, 草葉一友 Journal of Japanese Society of Pharmaceutical Oncology 41: 361-361, 2025. |
|---|
|
|
P-251. The example that we were associated with as a family pharmacist from the outpatient department to treatment at home as palliative care of patients with lung cancer sequentially 栄由佳1), 小橋紀子1), 福島綾2) Journal of Japanese Society of Pharmaceutical Oncology 41: 362-362, 2025. |
|---|
|
|
P-253. Construction of the evidence for occupational exposure to cyclophosphamide measures using the cytotoxicity test 上田裕1), 中野貴文2), 小迫知弘3), 佐藤朝光4), 大薮康平5), 真島宏太6), 眞崎晃6), 角康隆6), 吹上勇真1), 宮崎元康7), 今給黎修7), 緒方憲太郎8) Journal of Japanese Society of Pharmaceutical Oncology 41: 363-363, 2025. |
|---|
|
|
P-255. JASPO supervision "duties guidance about the cancer medical therapy of the family pharmacist, drugstore" usefulness investigation 坂本亜矢子1), 川畑大輔1), 片岡礼奈1), 松田美祐1), 勝山ゆずほ1), 水上義忠1), 中川史津1), 栄由佳2), 小橋紀子2) Journal of Japanese Society of Pharmaceutical Oncology 41: 364-364, 2025. |
|---|
|
|
P-257. Anticancer medicine decontamination effect by P-CLEAR(R) in the chemotherapy center 杉野善彦1), 浅野寿規1), 馬場未沙子1), 青井美樹2), 龍華朱音3), 大島有美子1), 桜田宏明1) Journal of Japanese Society of Pharmaceutical Oncology 41: 365-365, 2025. |
|---|
|
|
P-259. Fact-finding about the pharmacist duties of the foreign cancer treatment section in the 2024 cancer practice cooperation base Hospital, and the like 盛川敬介1,17), 高橋郷2,17), 本田泰斗3,17), 飯塚雄次4,17), 石原由起子5,17), 上ノ段友里6,17), 浮谷聡7,17), 内坪敬太8,17), 小枝伸行9,17), 長渡亜子10,17), 畠山智明11,17), 本田雅志12,17), 松浦綾子13,17), 餅原弘樹14,17), 濃沼政美15,17), 樋口昇大16,17), 松井礼子16,17) Journal of Japanese Society of Pharmaceutical Oncology 41: 366-366, 2025. |
|---|
|
|
P-261. Examination of the drug costs reduction effect by the adoption standard change of azacitidine 関真咲季, 松島美知子, 花谷直美, 山口智子, 森崎結香子, 谷垣柊乃介, 宇野洋司, 小杉三弥子, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 41: 367-367, 2025. |
|---|
|
|
P-263F. Importance of the specialty pharmacist seeing it from intervention contents and the adoption situation of the suggestion to the foreign cancer chemotherapy patients in the specialized medical institution cooperation drugstore 安留輝, 中村亜優実, 和田憲周 Journal of Japanese Society of Pharmaceutical Oncology 41: 368-368, 2025. |
|---|
|
|
P-265. Examination of efforts and usefulness for the calculation of the cancer medical therapy system full addition and the problem 眞弓健介, 藤本愛理, 佐藤朋佳, 堀南奈子, 下村真代, 小山田純治 Journal of Japanese Society of Pharmaceutical Oncology 41: 369-369, 2025. |
|---|
|
|
P-267. The use situation investigation of the immunosuppressive drug before and after cancer treatment in patients with rheumatoid arthritis 井上将貴1,2), 平田一耕1,2), 大場啓貴1,2,3), 木崎悠斗1), 舟越亮寛1,4) Journal of Japanese Society of Pharmaceutical Oncology 41: 370-370, 2025. |
|---|
|
|
P-269. Introduction of the cancer practice hospital cooperation training in Rousaibyoin, Yokohama 石井信幸1), 稲田佑亮2), 黒須智宏2), 京谷充崇2), 小倉絵里奈2), 齊藤佳奈2), 貞重実央2), 安積奈々美2), 大野垣陽子2), 松村敦子3), 月岡良太3), 角田誠一2) Journal of Japanese Society of Pharmaceutical Oncology 41: 371-371, 2025. |
|---|
|
|
P-271. Efforts of the cancer practice hospital cooperation training in the Fukuoka University Chikushi Hospital 柿本秀樹1), 福江悠香1), 吹上勇真1), 萩原知佳1), 鵜木亜矢子1), 中島章雄1,2), 眞崎晃3), 内山将伸3,4), 松尾宏一3,4), 後藤美和1), 宮崎元康1,2), 今給黎修1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 372-372, 2025. |
|---|
|
|
P-273. Report on cancer treatment hospital collaboration training: lessons learned and challenges 神崎眞依1), 高橋俊明1,2), 高橋恵2) Journal of Japanese Society of Pharmaceutical Oncology 41: 373-373, 2025. |
|---|
|
|
P-275. The cancer practice hospital cooperation training and subsequent drugstore duties report 宮本泰光 Journal of Japanese Society of Pharmaceutical Oncology 41: 374-374, 2025. |
|---|
|
|
P-277. The role of the drugstore pharmacist through the cancer practice hospital cooperation training and intervention to medical treatment 古閑和崇1), 柿本秀樹2), 藤原早友里1), 薬師神壮3), 上妻弘明3) Journal of Japanese Society of Pharmaceutical Oncology 41: 375-375, 2025. |
|---|
|
|
P-279. Efforts of the continuation support system after the cancer practice hospital cooperation training 柴田直樹, 横川貴志, 中村匡志, 天川佳洋, 橋本幸輝, 蓑輪雄一, 山田玲子, 山口正和 Journal of Japanese Society of Pharmaceutical Oncology 41: 376-376, 2025. |
|---|
|
|
P-002. Frequencies of retching vomiting in the Zolbetuximab eight hours administration 藤田行代志, 村岡ありさ, 井上千菜美, 新井隆広, 川島菜保子, 齊藤妙子 Journal of Japanese Society of Pharmaceutical Oncology 41: 377-377, 2025. |
|---|
|
|
P-004F. Use fact-finding of the opioid analgesic at the hematopoietic stem cell transplantation in the pediatric special hospital 芦原まいか, 青木美穂, 藤井咲希, 藤田愛美, 垣尾尚美, 陣田剛志, 末森千加子, 河原香織, 石田達彦 Journal of Japanese Society of Pharmaceutical Oncology 41: 378-378, 2025. |
|---|
|
|
P-006. Self-control case series study about the acute renal failure after the gastric-acid secretion antagonist administration start in patients with cancer 鈴木康介1,2), 渡邊亜矢子1,3), 桐生嘉浩4), 井上永介5), 百賢二1,6) Journal of Japanese Society of Pharmaceutical Oncology 41: 379-379, 2025. |
|---|
|
|
P-008. A case that information sharing by the PHR application contributed to early intervention of irAE 辻茉莉香1), 溝口明子1), 塚川麻利子1), 市川瑞季1), 松浦千裕1), 村山三佳1), 淺倉淳子1,2), 田橋美佳1,3), 加藤美紀1,4), 安部圭紀5), 五十嵐文1), 五十嵐俊1), 山本郁生1) Journal of Japanese Society of Pharmaceutical Oncology 41: 380-380, 2025. |
|---|
|
|
P-010. A retrospective study of injection site reactions following administration of trastuzumab, pertuzumab, and borhyaluronidase alfa in breast cancer patients 団迫湊1), 土谷裕貴1), 是枝哲平1), 倉橋基尚1), 新田佳苗2), 濱田千早3), 谷本寿代3) Journal of Japanese Society of Pharmaceutical Oncology 41: 381-381, 2025. |
|---|
|
|
P-012. The effectiveness and safety of mirogabalin and duloxetine for peripheral neuropathy with the anticancer medicine 松山卓矢, 木村美智男, 郷真貴子, 山田志緒里, 西村充礼, 村瀬寛美, 宇佐美英績 Journal of Japanese Society of Pharmaceutical Oncology 41: 382-382, 2025. |
|---|
|
|
P-014. Examination of the renal function evaluation by enzyme method and the Jaffe method of pemetrexed treated patients and the risk assessment of the neutropenia 大原沙織, 六車龍介, 大前隆広, 汐谷恵, 福井由美子 Journal of Japanese Society of Pharmaceutical Oncology 41: 383-383, 2025. |
|---|
|
|
P-016. Investigation for protein urine early expression predictions in the Atezolizumab + bevacizumab combination therapy for the unresectable hepatocellular carcinoma 西和哉1), 川田彰彦1), 佐々木崇1), 藤坂泰之2), 赤羽武弘2) Journal of Japanese Society of Pharmaceutical Oncology 41: 384-384, 2025. |
|---|
|
|
P-018. Zolbetuximab (VYLOY(R)) Administration at Ehime Prefectural Central Hospital 西畑友尋1), 西原愛実1), 明下佳祐1), 新居田能章1), 村井望1), 十亀將輝1), 末廣拓1), 越智啓介1), 宇都本孝夫1), 松岡葉子1), 織田高子1), 玉井宏一1), 池内靖恵2), 山下広2), 壷内栄治3), 烏谷政和1), 倉田知久1) Journal of Japanese Society of Pharmaceutical Oncology 41: 385-385, 2025. |
|---|
|
|
P-020. Fact-finding about the appearance after the breast cancer perioperative chemotherapy introduction using the scalp ice cradle 鈴木訓史1), 富樫友子2), 茂木綾子3), 伊藤淳3), 渡邉隆紀3) Journal of Japanese Society of Pharmaceutical Oncology 41: 386-386, 2025. |
|---|
|
|
P-022. Examination of the usefulness of the pinch measurement of the force in the evaluation method of CIPN 六車龍介1), 辻本勉2), 南のどか1), 國東祐美3), 山内紗綾香1), 大原沙織1), 大前隆広1), 汐谷恵1), 福井由美子1) Journal of Japanese Society of Pharmaceutical Oncology 41: 387-387, 2025. |
|---|
|
|
P-024. Investigation of the frequencies of the immune-mediated adverse event in the use of immune checkpoint inhibitor patients in our hospital and the measurement rate of use of the examination item 荻野健吾, 西村栄一, 近藤智幸, 簑島弓未子, 橋本光生 Journal of Japanese Society of Pharmaceutical Oncology 41: 388-388, 2025. |
|---|
|
|
P-026. Fact-finding of the cardiac activity evaluation in patients with epirubicin administration breast cancer of our hospital 脇由香里1), 松田浩明2), 野田晋司1) Journal of Japanese Society of Pharmaceutical Oncology 41: 389-389, 2025. |
|---|
|
|
P-028. Investigation about the onset of proteinuria situation, and the like in the bevacizumab administration 及川嵩人, 松葉智哉, 菊地秋子 Journal of Japanese Society of Pharmaceutical Oncology 41: 390-390, 2025. |
|---|
|
|
P-030. After the operation before operation of our hospital about the cardiac function diagnostic procedures enforcement situation and a treatment successful execution rate at the adjuvant chemotherapy 山崎朋子, 吉澤朝枝, 田島英, 長谷川芽萌, 大野もえこ, 木下沙織, 塩月智子, 櫻澤有紀 Journal of Japanese Society of Pharmaceutical Oncology 41: 391-391, 2025. |
|---|
|
|
P-032. Analysis of the expression situation and the risk factor of retching, vomiting in the trifluridine Tipiracil + bevacizumab combination therapy 三好孝法, 深澤真実, 和佐野英子, 高武嘉道, 筒井佑紀, 筒井結子, 藤瀬陽子, 大橋邦央, 橋本雅司 Journal of Japanese Society of Pharmaceutical Oncology 41: 392-392, 2025. |
|---|
|
|
P-034. The preliminary investigation that fixed its eyes on the possibility that SGLT2 inhibitor extended time to onset of proteinuria by the bevacizumab 増島広幸1), 田中怜2), 佐藤淳也2), 高橋瑞季1), 石川寛1), 佐藤哲1) Journal of Japanese Society of Pharmaceutical Oncology 41: 393-393, 2025. |
|---|
|
|
P-036. About pharmacist outpatient department of our hospital, the current situation of the cooperation full addition 朝岡裕樹, 宮本拓人, 星野有吾, 森真澄, 佐藤英和 Journal of Japanese Society of Pharmaceutical Oncology 41: 394-394, 2025. |
|---|
|
|
P-038. Effect of the povidone iodine mouth wash on oral mucositis in the CHOP-like therapy 大堀健史1), 近野祐里1), 出羽祐基1), 鎌倉政城1), 八尾尚樹1), 浅越康助2), 鍬田千草1) Journal of Japanese Society of Pharmaceutical Oncology 41: 395-395, 2025. |
|---|
|
|
P-040. Efforts of the regimen maintenance that allowed you to give Zolbetuximab easily 吉澤寛朗, 宇川このみ, 筒井寿穂, 工藤尚亨, 五十嵐玲子 Journal of Japanese Society of Pharmaceutical Oncology 41: 396-396, 2025. |
|---|
|
|
P-042. Use fact-finding of the peg filgrastim subcutaneous injection body pod preparation 景山花奈, 北村真奈美, 三好康介, 小田怜史, 渡部英明, 梅田勇一 Journal of Japanese Society of Pharmaceutical Oncology 41: 397-397, 2025. |
|---|
|
|
P-044. Fact-finding of the outpatient department cancer practice support by our hospital pharmacist for patients receiving treatment with injection anticancer medicine 東峻平1), 島貫裕実子1), 大橋養賢1), 工藤浩史1), 小室雅人2), 渡邊一史1), 石川紗衣1), 湯舟香春1), 松井礼子1), 西村富啓1) Journal of Japanese Society of Pharmaceutical Oncology 41: 398-398, 2025. |
|---|
|
|
P-046. Retrospective survey of the onset of hypothyroidism case that is an immune-mediated event in the Koto Hospital 池田美咲, 岡田侑子, 山室明子, 霍間ひろの, 早野奈々, 佐藤大輔 Journal of Japanese Society of Pharmaceutical Oncology 41: 399-399, 2025. |
|---|
|
|
P-048. A treatment result of the bevacizumab + trifluridine/Tipiracil therapy in the colon cancer chemotherapy and intervention effect of the pharmacist 堀口大輔, 橋本直美, 鬼丸俊司 Journal of Japanese Society of Pharmaceutical Oncology 41: 400-400, 2025. |
|---|
|
|
P-050. Usefulness evaluation of antiemesis measures according to extensive emetic risk (HEC) for Zolbetuximab-induced retching, vomiting (CINV) 南ひさこ1), 高崎修一1), 辻靖2), 土井綾子2), 千葉崇久1), 山岡怜央1), 北島聖也1), 坂東拓哉1) Journal of Japanese Society of Pharmaceutical Oncology 41: 401-401, 2025. |
|---|
|
|
P-052. About safe prescribed development and efforts in the cancer chemotherapy enforcement 大田哲也, 浜村圭惟, 岡村明昇, 右田裕二, 岡村俊則 Journal of Japanese Society of Pharmaceutical Oncology 41: 402-402, 2025. |
|---|
|
|
P-054F. Examination of a pre-rear investigation and the maintenance therapy choice of progress ovarian cancer using the KELIM level 遠藤恵, 小笠裕斗, 上津沙織, 塚原邦浩, 小倉秀美 Journal of Japanese Society of Pharmaceutical Oncology 41: 403-403, 2025. |
|---|
|
|
P-056. The pharmacist outpatient department follow situation investigation for breast cancer internal use anticancer agent-treated patients 高木淳也, 海野祥生, 張友樹, 細田菜摘, 山口琴子, 木原星衣, 鹿間友絵, 前田美紀, 生田和之, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 41: 404-404, 2025. |
|---|
|
|
P-058. Evaluation of the alleviation of fever effect with the acetaminophen injection 30 minutes administration 生田和之, 海野祥生, 高木淳也, 張友樹, 細田菜摘, 山口琴子, 木原星衣, 鹿間友絵, 前田美紀, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 41: 405-405, 2025. |
|---|
|
|
P-060F. Comparison between 5HT3 receptor blocker + dexamethasone and antiemesis effect with the dexamethasone alone for the slight emetic risk chemotherapy 川満啓司, 林稔展, 脇岡葵, 牛尾聡一郎, 江川孝 Journal of Japanese Society of Pharmaceutical Oncology 41: 406-406, 2025. |
|---|
|
|
P-062F. Investigation about the prescription actual situation and the change of the Chinese medicine of patients receiving cancer medical therapy 太田博暁, 安武夫 Journal of Japanese Society of Pharmaceutical Oncology 41: 407-407, 2025. |
|---|
|
|
P-064F. Role of the drugstore pharmacist for the safe enforcement of the foreign cancer chemotherapy using the antimetabolite 工藤可奈子1), 一戸秀太2), 吉川美穂3), 伊藤将4), 長谷川佳孝4), 月岡良太4), 大石美也4) Journal of Japanese Society of Pharmaceutical Oncology 41: 408-408, 2025. |
|---|
|
|
P-066. It is fact-finding of the drug information about the final concentration after the temperature condition, the shading condition and the dilution after the dissolution at injection antitumor agents preparation 重村明香, 坂本靖宜, 長谷川拓也, 吉友葵, 宇山佳奈, 小泉宏史, 清水絢子, 安島秀友, 井出和男, 小池博文, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 41: 409-409, 2025. |
|---|
|
|
P-068. About making and the operation of the Zolbetuximab administration flowchart that a pharmacist leads 玉田広明, 飯田遼, 安藤寛子, 猪瀬成史, 椿浩之 Journal of Japanese Society of Pharmaceutical Oncology 41: 410-410, 2025. |
|---|
|
|
P-070. Electrocardiographic usefulness evaluation in the cancer treatment with the anthracycline anticancer medicine-related cardiac activity disorder 小島健一1), 大神正宏1), 立原茂樹1), 島田浩和1), 小島友恵1), 柴このみ1), 植田清孝1), 鈴木智貴1), 岡部雄太2), 鈴木美加1) Journal of Japanese Society of Pharmaceutical Oncology 41: 411-411, 2025. |
|---|
|
|
P-072F. Safe examination of the PCE induction therapy of patients with head and neck cancer in the Tokyo Dental College Ichikawa General Hospital 沼尻美樹, 加賀麻友美, 山中優子, 加藤奈々美, 門田佳子 Journal of Japanese Society of Pharmaceutical Oncology 41: 412-412, 2025. |
|---|
|
|
P-074. Improvement of pharmacist interview before medical examination and intelligence ... utilizing efficiency - eDIARY system 都築竜太1), 香取哲哉1), 河本怜史1), 木村敦1), 吉田裕紀1), 青柳友彦1), 金澤亜梨沙1), 塚田麻実1), 藤澤知美1), 荒木章宏1), 岡元るみ子2), 小茂田昌代1), 出雲貴文1) Journal of Japanese Society of Pharmaceutical Oncology 41: 413-413, 2025. |
|---|
|
|
P-076. Efficacy of prophylactic dexamethasone administration for skin disorders caused by enfortumab vedotin 今村有那, 長尾嘉真, 石嶋麗, 赤岩愛記, 大塚健太郎, 大栗宝子, 長山佳之, 小川千晶, 軍司剛宏 Journal of Japanese Society of Pharmaceutical Oncology 41: 414-414, 2025. |
|---|
|
|
P-078. Fact-finding about the potential drug interactions in Apalutamide and the Enzalutamide remedy patients 松下尚弘, 古賀清弘, 田中早穂子, 黒木吟美, 野中敏治, 吉田実 Journal of Japanese Society of Pharmaceutical Oncology 41: 415-415, 2025. |
|---|
|
|
P-080F. Fact-finding of retching, the vomiting expression situation in the T-DXd administration for patients with HER2-positive breast cancer 林田悠佳1), 小川千昌1), 長尾嘉真1), 赤岩愛記1), 大栗宝子1), 大塚健太郎1), 長山佳之1), 石嶋麗1), 今村有那1), 松井哲2), 軍司剛宏1) Journal of Japanese Society of Pharmaceutical Oncology 41: 416-416, 2025. |
|---|
|
|
P-082. Examination of the effectiveness of the cold compress in the dermatopathy of the mouse extravasation model with oxaliplatin 平山純鈴1), 牧島里紗1), 野澤 (石井) 玲子2), 杉富行1) Journal of Japanese Society of Pharmaceutical Oncology 41: 417-417, 2025. |
|---|
|
|
P-084. Risk factors for infusion reactions after initial administration of Phesgo 齋藤有華, 古原優也, 中村安孝 Journal of Japanese Society of Pharmaceutical Oncology 41: 418-418, 2025. |
|---|
|
|
P-086. Exploratory study that the patients that a drugstore pharmacist measures SpO2 receive the intervention with the telephone, examine early detection of the interstitial lung disease whether it is connected 青木翔太1), 今井淳仁1), 渡邉智重5,1), 鶴田敬子1), 山本葉瑠奈1), 堀成実4), 堀優太4,1), 山内惠太3), 市村友樹2) Journal of Japanese Society of Pharmaceutical Oncology 41: 419-419, 2025. |
|---|
|
|
P-088F. The multi-type of job cooperation and tool making to give Zolbetuximab safely 磯村奈帆子, 幸田恭治, 栗林左知 Journal of Japanese Society of Pharmaceutical Oncology 41: 420-420, 2025. |
|---|
|
|
P-090. Fact-finding of the dexamethasone coinfusion for the vascular pain of oxaliplatin of our hospital 山口琴子, 生田和之, 木原星衣, 鹿間友絵, 前田美紀, 高木淳也, 海野祥生, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 41: 421-421, 2025. |
|---|
|
|
P-092. Use fact-finding in our hospital of the Durvalumab + Tremelimumab + chemotherapy 後藤桂輔, 松木美緒, 岩田梨沙, 片岡優太, 荒木有希, 若本あずさ, 初山多恵, 佐藤秀紀 Journal of Japanese Society of Pharmaceutical Oncology 41: 422-422, 2025. |
|---|
|
|
P-094. Usefulness - pharmacist duties efficiency and patients questionnaire results ... of the use of video at internal use anticancer agent introduction 松浦雅人, 北澤薫, 吉田仁志 Journal of Japanese Society of Pharmaceutical Oncology 41: 423-423, 2025. |
|---|
|
|
P-096. One case of patients with breast cancer that led to long-term use continuation of the Abemaciclib by the intervention of the health insurance pharmacy pharmacist 糸賀美穂1), 小出英里1), 中野智恵美1), 今出仁美1), 福間宏1), 玉木比抄子1), 海田奈緒美1), 大棚貴史1), 熊谷岳文2) Journal of Japanese Society of Pharmaceutical Oncology 41: 424-424, 2025. |
|---|
|
|
P-098. A case which we conducted intervention to supportive care in the supporting BEP therapy after the operation and were able to accomplish without a delay of the treatment plan and the antitumor agents reduction 末松耕輔1), 真島美佳1), 水田秀貴1), 佛坂章子1), 佐野雅彦1), 佐藤暢晃2), 諸隈太2), 草葉一友1) Journal of Japanese Society of Pharmaceutical Oncology 41: 425-425, 2025. |
|---|
|
|
P-100. 1 case that it became the urinary retention after the oral morphine start, and was improved after the switching to fentanyl patch 田中祐介 Journal of Japanese Society of Pharmaceutical Oncology 41: 426-426, 2025. |
|---|
|
|
P-102. A case of serous retinal detachment discovered through follow-up by hospital pharmacists and pharmacy pharmacists in a colon cancer patient receiving encorafenib and binimetinib 石川遥介1), 丸山真一2), 富田匡彦3), 清水正幸4), 菅野浩2), 下前博史1) Journal of Japanese Society of Pharmaceutical Oncology 41: 427-427, 2025. |
|---|
|
|
P-106. Pharmaceutical intervention for the adverse event of the edge drumstick nib 藤本真規子1), 澤野麻子2), 西尾雄司3) Journal of Japanese Society of Pharmaceutical Oncology 41: 429-429, 2025. |
|---|
|
|
P-108. One case that led to treatment of the SIADH with a tracing report for the suit of patients during use of ICI 安斎沙織1), 岡田浩司3), 平川寛之3), 宮田広樹2) Journal of Japanese Society of Pharmaceutical Oncology 41: 430-430, 2025. |
|---|
|
|
P-110. Risk factors for severe cytokine release syndrome caused by epcoritamab 吉冨加奈子, 計良貴之, 丸本かおり, 荒井園枝, 小林加寿夫 Journal of Japanese Society of Pharmaceutical Oncology 41: 431-431, 2025. |
|---|
|
|
P-112. One case that Elobixibat might be involved in for an excretion delay of the high-dose methotrexate 南雲昭人, 杉田あすか, 磯知輝 Journal of Japanese Society of Pharmaceutical Oncology 41: 432-432, 2025. |
|---|
|
|
P-114. A case which developed acute pancreatitis after the GEM+nabPTX therapy and the mFOLFIRINOX therapy for progress recurrence pancreatic cancer 稲田佑亮, 山後晴菜, 角田誠一 Journal of Japanese Society of Pharmaceutical Oncology 41: 433-433, 2025. |
|---|
|
|
P-116. Cooperation of a drugstore pharmacist and the hospital pharmacist for the reduction of the oxaliplatin-induced vascular pain 福本佑希1), 大塚識稔2), 石井一也2), 神原康佑2), 岡田淳芳2), 伊藤将3), 長谷川佳孝3), 月岡良太3), 大石美也3) Journal of Japanese Society of Pharmaceutical Oncology 41: 434-434, 2025. |
|---|
|
|
P-118. A case in which intervention by a pharmacy pharmacist contributed to improving pain scores in a patient with peripheral sensory neuropathy caused by enfortumab vedotin 肥田佑実 Journal of Japanese Society of Pharmaceutical Oncology 41: 435-435, 2025. |
|---|
|
|
P-120. Progress report by eight police box magnetic field treatment device introduction to chemotherapy-induced peripheral neuropathy << CIPN >> patients 植田美希, 川村真理恵, 酒井由希子, 平山祐美, 長谷川依子, 柳田義一 Journal of Japanese Society of Pharmaceutical Oncology 41: 436-436, 2025. |
|---|
|
|
P-122. 1 case that tried hyposensitization for the early toxic eruption onset by the Osimertinib, and became available for treatment continuation 松原重征1), 関彩香1), 今井万治朗1), 藤原香織1), 伊藤陽一1), 小泉知展2) Journal of Japanese Society of Pharmaceutical Oncology 41: 437-437, 2025. |
|---|
|
|
P-124. A case in which interactions with selumetinib were avoided through collaboration with local medical institutions 吉川麻里子1), 鈴木大介2) Journal of Japanese Society of Pharmaceutical Oncology 41: 438-438, 2025. |
|---|
|
|
P-126. One case of the elderly patients whom scabies developed in during first glioblastoma postoperative chemoradiotherapy (the Stupp regimen) 廣瀬健一1), 青山優香1), 齊藤達也1), 古林園子1), 三沢美知代2), 市田泰彦1), 大賀優3), 関口昌利 Journal of Japanese Society of Pharmaceutical Oncology 41: 439-439, 2025. |
|---|
|
|
P-128F. 1 case that a pharmacist acquired a family pharmacist for patients with colon cancer given CAPOX therapy in the first year, and was able to support treatment successful execution 高倉浩平1), 溝上泰仁2,3), 内田月読1), 福手吉典1,2), 黒部健太郎4), 八坂瑞臣2) Journal of Japanese Society of Pharmaceutical Oncology 41: 440-440, 2025. |
|---|
|
|
P-130F. Two cases of pseudo renal failure by the Olaparib and guessed ovarian cancer 永沢峻之介1), 宮崎晃臣1), 谷口綾亮2), 新岡琢也1) Journal of Japanese Society of Pharmaceutical Oncology 41: 441-441, 2025. |
|---|
|
|
P-132. A case of skin disorders suspected to be caused by Vorhyaluronidase Alfa after switching to PHESGO(R) for HER2-positive breast cancer 海野祥生1), 高木淳也1), 吉田達也2), 王華帆3), 張友樹1), 細田菜摘1), 山口琴子1), 木原星衣1), 鹿間友絵1), 前田美紀1), 生田和之1), 加藤一郎1) Journal of Japanese Society of Pharmaceutical Oncology 41: 442-442, 2025. |
|---|
|
|
P-134. A case of metastatic breast cancer which resulted in uveal flame during Pembrolizumab administration 田頭尚士1), 秋山一郎2), 野上智弘2), 大倉裕祐1) Journal of Japanese Society of Pharmaceutical Oncology 41: 443-443, 2025. |
|---|
|
|
P-136. Our hospital's experience with epcoritamab treatment and its side effects 助畑歩1), 中村雄亮1), 太田秀一2), 小森均1) Journal of Japanese Society of Pharmaceutical Oncology 41: 444-444, 2025. |
|---|
|
|
P-138. A case that tardive diarrhea in the cancer chemotherapy was treated effectively with diet improvement 吉田英晃1), 野田美佳2), 三角孔史郎3), 邑瀬誠5), 深津英人4), 松井洸4), 山口浩4), 野村和彦4) Journal of Japanese Society of Pharmaceutical Oncology 41: 445-445, 2025. |
|---|
|
|
P-140. A case which led to consultation encouragement through telephone medication support (R) and Followcare 高橋一彦1), 鈴木直哉2), 谷口亮央2), 中島史雄3) Journal of Japanese Society of Pharmaceutical Oncology 41: 446-446, 2025. |
|---|
|
|
P-142. One case of patients with acquired cystic disease of kidney basalioma which caused extension of international normalized ratio (PT-INR) by combination of Lenvatinib and warfarin for prothrombin time 鳥居昌太1), 成田知弥2), 本間崇正1), 江崎秀樹1), 榊原隆志1), 滝本典夫1) Journal of Japanese Society of Pharmaceutical Oncology 41: 447-447, 2025. |
|---|
|
|
P-144. Three patients whom pneumocystis pneumonia developed in at the breast cancer dose-dense EC enforcement 伊藤弘美, 浅野寿規, 桜田宏明 Journal of Japanese Society of Pharmaceutical Oncology 41: 448-448, 2025. |
|---|
|
|
P-146. 1 case that correlation was found in in a peak concentration and a BNP level of the dasatinib at the pleural effusion retention that developed during dasatinib administration 中原良介1), 炭本隆宏1), 田中遼大1), 龍田涼佑1), 緒方正男2), 伊東弘樹1) Journal of Japanese Society of Pharmaceutical Oncology 41: 449-449, 2025. |
|---|
|
|
P-148F. One case that was connected for early detection of the interstitial pneumonia as a drugstore pharmacist noticed the slight cough which developed during Abemaciclib remedy 國原千穂美 Journal of Japanese Society of Pharmaceutical Oncology 41: 450-450, 2025. |
|---|
|
|
P-150. A case which developed bilateral central retinal artery atresia during nivolumab therapy 川崎美咲, 鈴木京美, 都築沙織, 下川福子, 羽成望, 相澤智代, 作山悠里, 後藤一馬 Journal of Japanese Society of Pharmaceutical Oncology 41: 451-451, 2025. |
|---|
|
|
P-152F. Investigation of progress, retching, the vomiting onset situation during Zolbetuximab administration for recurrent stomach cancer 小泉慶子1), 安藤洋介1), 熊澤里美1), 水野智博1), 松岡宏2), 山田成樹1) Journal of Japanese Society of Pharmaceutical Oncology 41: 452-452, 2025. |
|---|
|
|
P-154. One case of rectal cancer which evaded aggravation of the delayed type hypersensitivity by medicine medicine cooperation 竹田あかね1), 井上裕貴1), 小久保維菜1), 長岡宏一1), 伊藤武2), 山下克也2) Journal of Japanese Society of Pharmaceutical Oncology 41: 453-453, 2025. |
|---|
|
|
P-156. One case that intractable pain improved by changes from a high-dose hydromorphone note to methadone 天野敬大, 辻莉子, 野口宣之 Journal of Japanese Society of Pharmaceutical Oncology 41: 454-454, 2025. |
|---|
|
|
P-158F. The adverse event situation investigation of the Pembrolizumab combination regimen for the triple negative early stage breast cancer 小島卓也1), 柳田裕行1), 石井武男1), 小坂真吉2), 森千子2) Journal of Japanese Society of Pharmaceutical Oncology 41: 455-455, 2025. |
|---|
|
|
P-160. A case that methadone hydrochloride tablets were given for the cancerous pain of haemodialysis patients, and pain improvement was obtained 富田哲夫1), 古野孝明1), 林瑠衣子2), 浦野真一3) Journal of Japanese Society of Pharmaceutical Oncology 41: 456-456, 2025. |
|---|
|
|
P-162F. One case that a drugstore pharmacist dissolved the anxiety about the AI rotation of patients with AI-related muscles and bones syndrome, and there was change of prescription smoothly 國原貴弘 Journal of Japanese Society of Pharmaceutical Oncology 41: 457-457, 2025. |
|---|
|
|
P-164. One patient who lactic acidosis due to 5-FU developed during mFOLFOX6 treatment, but continues treatment while regulating a dose 風岡真実, 近江一太, 吉成宏顕, 神坐美弥子 Journal of Japanese Society of Pharmaceutical Oncology 41: 458-458, 2025. |
|---|
|
|
P-166. One patient who was treated effectively with ENCO+BINI+CET therapy after the Pembro therapy for colon cancer of BRAF mutation in the gene positive and MSI-H 赤井涼子1), 吉田憲司1), 橋本知世1), 戸口尚謙1), 中山博文2), 矢吹直寛1) Journal of Japanese Society of Pharmaceutical Oncology 41: 459-459, 2025. |
|---|
|
|
P-168. The case that affected transluminal administration by the simple suspension of the Tirabrutinib for central nerve origin lymphoma that we could not ingest 金正興1), 星茜1,2), 島本一志1,2), 竹中桃子3), 島田翔太郎4), 服部憲路4), 嶋村弘史1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 460-460, 2025. |
|---|
|
|
P-170. Efforts for the initial foreign introduction of the Zolbetuximab 小林由佳1), 大泉崇1), 東海林千裕1), 鈴木大雅1), 八鍬絵梨菜2), 庄司優子2), 鈴木修平3), 庄司喜恵1) Journal of Japanese Society of Pharmaceutical Oncology 41: 461-461, 2025. |
|---|
|
|
P-172. Usefulness of enforcement and the tracing report inflection of the pharmacist loanword for patients with cancer 小野航太郎1,2), 木村祐子1,2), 稲垣貴士1,2), 徳永愛美1,2), 市倉大輔1,2), 縄田修一1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 462-462, 2025. |
|---|
|
|
P-174. The intervention method to an outpatient using the Kyoto second Red Cross hospital and the pain-killer follow-up sheet by the health insurance pharmacy and future problem 加藤良隆, 福田喬士, 森正衣南, 渡邉愛梨, 林曜子, 廣野直美, 下野紀子, 友金幹視 Journal of Japanese Society of Pharmaceutical Oncology 41: 463-463, 2025. |
|---|
|
|
P-176. About the present situation of the intelligence in the cancer medical treatment medication counseling at the health insurance pharmacy 照屋千津子1,5), 石橋玲2,5), 細田真代3,5), 大野昭司4,5) Journal of Japanese Society of Pharmaceutical Oncology 41: 464-464, 2025. |
|---|
|
|
P-178. Resident result and problem to the foreign chemotherapy room of the person of reduction of working hours duty 豊田えり, 上田翠, 宇都宮暁, 眞壁秀樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 465-465, 2025. |
|---|
|
|
P-180. Efforts and result for the "cancer medical therapy system full addition" in our hospital calculation 岩瀬雅彦, 矢田部恵, 榎本直輝, 田中絵美悠, 岡村由佳, 田村和季, 渡邉里奈, 米田絢加, 河野光, 中野涼太, 赤木祐貴, 八代智子, 山岸美奈子 Journal of Japanese Society of Pharmaceutical Oncology 41: 466-466, 2025. |
|---|
|
|
P-182F. Fact-finding of the tracing report of the foreign cancer chemotherapy in our hospital 及川悠衣, 山口志郎, 多田純平, 関口知弘, 原伸好, 宮部貴識 Journal of Japanese Society of Pharmaceutical Oncology 41: 467-467, 2025. |
|---|
|
|
P-184. Usefulness evaluation of "the oral anticancer medicine explanation request book" 吉田宗広, 笹山潔 Journal of Japanese Society of Pharmaceutical Oncology 41: 468-468, 2025. |
|---|
|
|
P-186F. Research about the usefulness when we used PHR (Personal Health Record) for side effect measures during foreign cancer chemotherapy 櫻井理絵1), 藤川明男1), 平井成和2), 中島萌2), 池田貴之2), 児島由美2), 佐藤直子2), 土井啓員2), 中道節3), 増田雅行4), 横山晴子1) Journal of Japanese Society of Pharmaceutical Oncology 41: 469-469, 2025. |
|---|
|
|
P-188F. Suggestion contents investigation after the cancer medical therapy system full addition operational start in the Chuo, Asahi, Yokohama General Hospital 西海敬太, 川田史朗, 東垂水裕和, 小串興平 Journal of Japanese Society of Pharmaceutical Oncology 41: 470-470, 2025. |
|---|
|
|
P-190. Fact-finding of the prescription suggestion at by medical examination front of our hospital 北村渉, 岩立智, 木村康人, 曽根敦子, 平綿洋子, 丸谷善紀, 鈴木優司 Journal of Japanese Society of Pharmaceutical Oncology 41: 471-471, 2025. |
|---|
|
|
P-192F. Current situation and problem ... accompanied with the medicine medicine cooperation - cooperation full addition calculation start using the drug control summary tracing report in our hospital 東久美子, 向井光一朗, 久保田丈太 Journal of Japanese Society of Pharmaceutical Oncology 41: 472-472, 2025. |
|---|
|
|
P-194F. Consideration of the foreign chemotherapy drug intervention (from cooperation full addition calculation start) in our hospital 稲嶺盛佳1), 與世平一起2), 上地美奈子1), 宮城琢2) Journal of Japanese Society of Pharmaceutical Oncology 41: 473-473, 2025. |
|---|
|
|
P-196. It is task shift/share ... from ... physician to a pharmacist about the calculation situation of pharmacist outpatient department establishment and the cancer medical therapy system full addition 松本菜摘1), 大畑彩也香1), 飯塚聖子2) Journal of Japanese Society of Pharmaceutical Oncology 41: 474-474, 2025. |
|---|
|
|
P-198F. Process and the results report until cooperation full addition calculation realized by the cooperation of the multi-type of job 杉山知世, 増山翠, 樺山智一, 眞原達男 Journal of Japanese Society of Pharmaceutical Oncology 41: 475-475, 2025. |
|---|
|
|
P-200. Does the reporting about the foreign cancer medical treatment from a medical institution have an influence on the pharmaceutical intervention to patients with cancer at the specialized medical institution cooperation drugstore? 原田素子1), 本田雅志1), 江淵愛1), 牧りえ1), 小野杏佳子1), 山野聡1), 白谷莉世1), 福島絵美2) Journal of Japanese Society of Pharmaceutical Oncology 41: 476-476, 2025. |
|---|
|
|
P-202. Efforts for the revision of the treatment reporting book in meeting held medicine medicine cooperation liaison meeting "Polaris" 長山佳之, 小川千晶, 長尾嘉真, 赤岩愛記, 大塚健太郎, 大栗宝子, 今村有那, 石嶋麗, 軍司剛宏 Journal of Japanese Society of Pharmaceutical Oncology 41: 477-477, 2025. |
|---|
|
|
P-204. Efforts (the second report) for the calculation of the cancer medical therapy system full addition 松浦志保, 田島博樹, 山田裕之 Journal of Japanese Society of Pharmaceutical Oncology 41: 478-478, 2025. |
|---|
|
|
P-206. About the evaluations from an establishment approach of the pharmacist outpatient department to the current situation and a future problem 守山十和子, 税所美幸, 柴田雅之, 岩切詩子 Journal of Japanese Society of Pharmaceutical Oncology 41: 479-479, 2025. |
|---|
|
|
P-208. Efforts of the pharmaceutical medicine cooperation system reinforcement utilizing the pharmacist outpatient department in the cancer medical therapy 鈴木敦詞1), 鈴木大吾1), 中村敏史1), 坂田洋1), 服部芳明2) Journal of Japanese Society of Pharmaceutical Oncology 41: 480-480, 2025. |
|---|
|
|
P-210. The current situation of pharmacist outpatient department and the system full addition calculation in our hospital 永田卓也1,2), 渡邊亜矢子2,3), 大城真理奈1,2), 久知良礼美1,2), 太田品子2,3), 柏原由佳1,2) Journal of Japanese Society of Pharmaceutical Oncology 41: 481-481, 2025. |
|---|
|
|
P-212. Efforts and report about the Zolbetuximab administration by the multi-type of job 田口諒1), 石川寛1), 川上武志2), 川崎和広3), 永田菜美子1), 小柴聖史1), 杉山洋介1), 鴨志田武1), 横野友亮1), 佐藤哲1) Journal of Japanese Society of Pharmaceutical Oncology 41: 482-482, 2025. |
|---|
|
|
P-214F. Comparison of the molecular target medicine, eye disorders of the immune checkpoint inhibitor using the side effect mapping 小池光1), 齋藤ひかり1), 立田澪香1), 戸辺七海1), 前島多絵1), 岩本義弘2), 渡邊真知子1), 板垣文雄1) Journal of Japanese Society of Pharmaceutical Oncology 41: 483-483, 2025. |
|---|
|
|
P-216. Case series about the use of the online qualification confirmation system of patients with cancer in the health insurance pharmacy 高橋希1), 角佳亮2), 伊藤明日香1) Journal of Japanese Society of Pharmaceutical Oncology 41: 484-484, 2025. |
|---|
|
|
P-218F. Study on oral antitumor agents and interaction prediction of the acid-secreting antagonist based on pH - solubility curve 禹姚朱, 河野裕太, 前島多絵, 渡邊真知子, 板垣文雄 Journal of Japanese Society of Pharmaceutical Oncology 41: 485-485, 2025. |
|---|
|
|
P-220F. Study on visualization of the pharmaceutical products price in the cancer medical therapy regimen 玉水雄大, 前島多絵, 渡邊真知子, 板垣文雄 Journal of Japanese Society of Pharmaceutical Oncology 41: 486-486, 2025. |
|---|
|
|
P-222. Mention situation comparison of alerting it about the perioperative use of the cancer molecules target medicine in package inserts, and the like 田中雄太1), 槇田崇志1), 佐田光1), 竹松龍人1), 猪田宏美1), 岩田直大1), 寺本賀一1), 蔵田靖子1), 目黒唯奈2), 岡拓己2), 中谷真緒2), 濱野裕章1,2), 村川公央1), 座間味義人1) Journal of Japanese Society of Pharmaceutical Oncology 41: 487-487, 2025. |
|---|
|
|
P-224. Attempt ... for herpes zoster therapeutic drug academic D tailing - individual treatment optimization in patients with cancer 杉山奈津子1), 出雲貴文2), 木村聡子3), 鈴木邦彦4), 頓宮美樹5), 長澤宏之6), 宗像千恵7), 森崎隆博2), 紺野奇重1), 辻稔1), 永井尚美8), 中谷善彦1), 平川聡史9), 岸達生10), 小茂田昌代2) Journal of Japanese Society of Pharmaceutical Oncology 41: 488-488, 2025. |
|---|
|
|
P-226. Efforts for the closed system anesthesia drug transfusion system (CSTD) extended introduction in our hospital 原田真由美, 岩鼻優, 渡邊雅明, 市川卓哉, 諏訪淳一, 益子里美 Journal of Japanese Society of Pharmaceutical Oncology 41: 489-489, 2025. |
|---|
|
|
P-228. Efforts for the efficiency of the regimen check system in our hospital 西原愛実, 明下佳祐, 新居田能章, 村井望, 十亀將輝, 末廣拓, 越智啓介, 宇都本孝夫, 松岡葉子, 織田高子, 伊藤智徳, 西畑友尋, 玉井宏一, 烏谷政和, 倉田知久 Journal of Japanese Society of Pharmaceutical Oncology 41: 490-490, 2025. |
|---|
|
|
P-230. Attitude survey of the pharmacist about the renal function rating system at anticancer agent doses setting 小林綾子1), 近藤悠希2), 横溝綾子3), 前田幹広1), 湊川紘子1), 野崎智椰1), 濱野公俊1), 坂上逸孝1) Journal of Japanese Society of Pharmaceutical Oncology 41: 491-491, 2025. |
|---|
|
|
P-232. Efforts of our hospital for the hepatitis B reactivation prevention in the cancer chemotherapy 武田啓子, 山極恒平, 川嵜真太郎, 仲井彩華, 藤井祐里愛, 青山由布子, 石合徹也 Journal of Japanese Society of Pharmaceutical Oncology 41: 492-492, 2025. |
|---|
|
|
P-234F. Examination about the attitude survey of the anticancer agent exposure to our hospital nurse measures 森本江美1), 横山亜紀2), 山崎里美2), 向林寿祥1), 中濱智則3), 百瀬均3), 平尾周也3) Journal of Japanese Society of Pharmaceutical Oncology 41: 493-493, 2025. |
|---|
|
|
P-236F. A case which effect of treatment of the Everolimus was thought to attenuate by carbamazepine combination 田辺憲人 Journal of Japanese Society of Pharmaceutical Oncology 41: 494-494, 2025. |
|---|
|
|
P-238. Construction and evaluation of the online inspection system at anticancer agent preparation using a tablet terminal 神垣輝美, 三嶋直輝, 得地美帆, 畑賢太, 藤村拓也, 伊藤拓, 山本浩史 Journal of Japanese Society of Pharmaceutical Oncology 41: 495-495, 2025. |
|---|
|
|
P-240. Intervention - by the specialty pharmacist to the anticancer medicine administration of oral anticancer medicine method that assumed analysis - side effect of prescription suggestion contents in the pharmacist outpatient department an intervention opportunity 村瀬寛美, 木村美智男, 郷真貴子, 山田志緒里, 西村充礼, 松山卓矢, 松山里奈, 宇佐美英績 Journal of Japanese Society of Pharmaceutical Oncology 41: 496-496, 2025. |
|---|
|
|
P-242. Examination of the generation AI inflection in the inspection support of cancer medical therapy regimen contents 槇枝大貴, 黒田智, 道原あやな, 丸尾陽成, 奥田浩人, 成本由佳, 猪田宏美, 濱野裕章, 西原茂樹, 座間味義人 Journal of Japanese Society of Pharmaceutical Oncology 41: 497-497, 2025. |
|---|
|
|
P-244. Importance (mainly on extravasation correspondence) of the intervention of the pharmacist for the incident accident at the cancer medical therapy 橋本直美, 堀口大輔, 鬼丸俊司 Journal of Japanese Society of Pharmaceutical Oncology 41: 498-498, 2025. |
|---|
|
|
P-246. Evaluation of the introduction of a prescription audit checklist for lenalidomide and pomalidomide 佐竹智規, 加藤良隆, 江島智彦, 若林祥子, 堀内あす香, 小森玉緒, 友金幹視 Journal of Japanese Society of Pharmaceutical Oncology 41: 499-499, 2025. |
|---|
|
|
P-248. Investigation of the examination for irAE, situation after the checkpoint inhibitor administration in our hospital of immunity 田中昭洋, 大西翔太, 高取秀人, 後藤卓也, 萱野勇一郎 Journal of Japanese Society of Pharmaceutical Oncology 41: 500-500, 2025. |
|---|
|
|
P-250F. Investigation about the role in the pharmacist specialized in foreign cancer treatment and the anticancer agent study session demand for patients 千葉光太1), 浅田猛大2) Journal of Japanese Society of Pharmaceutical Oncology 41: 501-501, 2025. |
|---|
|
|
P-252. The effect that educational intervention gives in the HPV vaccine knowledge of the pharmacist and recommended will: Randomized trial 湧井宣行1), 渡邉舞1), 菊池真由美2) Journal of Japanese Society of Pharmaceutical Oncology 41: 502-502, 2025. |
|---|
|
|
P-254. The effect that the case conference in the drugstore gives to quality and the quantity of the tracing report 渡辺富美子 Journal of Japanese Society of Pharmaceutical Oncology 41: 503-503, 2025. |
|---|
|
|
P-256. Evaluation of the persistent anticancer medicine pollution inhibitory effect by the daily life cleaning using P-CLEAR 福岡智宏, 山本泰大, 林宏紀, 青木さやか, 出口裕子 Journal of Japanese Society of Pharmaceutical Oncology 41: 504-504, 2025. |
|---|
|
|
P-258. About the ePRO introduction to foreign chemotherapy patients in our hospital 日下田葵, 橋口宏司, 横山敦, 佐伯朋哉, 原田優, 久下柊子, 中島研 Journal of Japanese Society of Pharmaceutical Oncology 41: 505-505, 2025. |
|---|
|
|
P-260. Exposure investigation after the closed system anesthesia transportation system introduction drug expansion 赤澤珠絵, 山極春子, 久保田将史, 千葉理恵, 谷健太郎, 阿部直樹 Journal of Japanese Society of Pharmaceutical Oncology 41: 506-506, 2025. |
|---|
|
|
P-262. About the current situation of the cancer medical therapy system full addition calculation in the JCHO Gunma center Hospital 千吉良幸子, 小材直人, 西場弘美, 新木美枝, 蟻川勝 Journal of Japanese Society of Pharmaceutical Oncology 41: 507-507, 2025. |
|---|
|
|
P-264F. Change of the knowledge of cancer by the cancer supporter training lecture for local inhabitants 滋野彩夏1), 太田直美2), 尹享月3), 向井啓1), 小森浩二1), 河田興1), 小西麗子1) Journal of Japanese Society of Pharmaceutical Oncology 41: 508-508, 2025. |
|---|
|
|
P-266. Assessment of exposure risk when using the Antileak(R) fully integrated infusion set 小澤勇人1), 秋山千恵2), 鈴木雄一郎1), 相差範子1), 中村友美1), 宮原勇人1), 長谷川久美1) Journal of Japanese Society of Pharmaceutical Oncology 41: 509-509, 2025. |
|---|
|
|
P-268. About exposure investigation after the closed system anesthesia drug transportation system (CSTD) introduction in our hospital 多田純平1), 野田拓誠2), 及川悠衣1), 関口知弘1), 山口志郎1), 原伸好1), 宮部貴識1) Journal of Japanese Society of Pharmaceutical Oncology 41: 510-510, 2025. |
|---|
|
|
P-270. About the cancer practice hospital cooperation training system in the large Hannan medical center 簗瀬真利, 佐々木祐太, 植田裕美, 庄野裕志, 櫛田宏幸, 佐光留美 Journal of Japanese Society of Pharmaceutical Oncology 41: 511-511, 2025. |
|---|
|
|
P-272. Own change before and after the cancer practice hospital cooperation training 田崎史弥1), 合津貴志2), 渋谷昌弘3), 中村文哉3), 阿部真也3), 五十嵐健祐3), 松井洸4), 山口浩4), 田崎政則2), 野村和彦4) Journal of Japanese Society of Pharmaceutical Oncology 41: 512-512, 2025. |
|---|
|
|
P-274F. Of in connection with a cancer practice hospital cooperation training report in the JA Onomichi General Hospital after the training, actually 川原邦仁1), 佐藤一求1), 比良大輔1), 栗原晋太郎1), 畝本由貴1), 世良真愛子1), 三吉由佳2), 別所千枝1) Journal of Japanese Society of Pharmaceutical Oncology 41: 513-513, 2025. |
|---|
|
|
P-276. Drugstore role reinforcement through the cancer practice hospital cooperation training and improvement of the knowledge and intervention technology 高橋翔太1), 仲矢侑希子1), 柳井英里1), 木下由美子1), 本庄弘史1), 小嶋恵1), 佐々木達也2), 北村仁2), 秋村夏花2), 谷口公章3), 小嶋祐一郎1), 葉田昌夫2), 下川要二4) Journal of Japanese Society of Pharmaceutical Oncology 41: 514-514, 2025. |
|---|
|
|
P-278. One case that intervened in the cancer practice hospital cooperation training 大谷拓輝 Journal of Japanese Society of Pharmaceutical Oncology 41: 515-515, 2025. |
|---|
|
|
P-280. Utilization by Yokohama medical center cancer practice hospital cooperation training report and drugstore duties 草野敦司 Journal of Japanese Society of Pharmaceutical Oncology 41: 516-516, 2025. |
|---|
|
|
Clinical tumor Pharmaceutical Society (JASPO) member fact-finding 2024 results report in Japan 中島美紀1,2), 長久保久仁子1,3), 小笠原信敬1,4), 齋藤瑛一1,5), 佐藤由美子1,9), 田中智枝1,6), 虎石竜典1,7), 久田健登1,10), 前原央奈1,8) Journal of Japanese Society of Pharmaceutical Oncology 41: 517-517, 2025. |
|---|
